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radiotheraPy for Prostate cancer
Around 8000 men are diagnosed with prostate cancer in the Netherlands every year (1). With 
the exception of skin cancer, it is the most common type of cancer in men. There are several 
ways to treat prostate cancer: hormonal therapy, radical prostatectomy, brachytherapy and 
external beam radiotherapy or a combination of these. A large part of the patients is treated 
with external beam radiotherapy. Three-dimensional conformal radiotherapy has been the 
standard technique for more than a decade. 
In three-dimensional conformal radiotherapy a computed tomography (CT) scan, called a 
planning CT scan, is performed in order to image the prostate and the surrounding organs. The 
physician delineates the prostate and anatomical structures that may cause radiation-induced 
toxicity, the organs at risk. Using this planning CT scan a treatment plan is made with the goal 
to distribute a high radiation dose in the prostate and a minimal dose in organs at risk, like 
the rectum. To achieve this goal radiation beams incident from various directions are created 
conform to the contour of prostate, avoiding the organs at risk. However, there are several 
uncertainties regarding delineation of the planning CT scan, deformation and movement of 
the prostate and patient (2). Therefore a margin of commonly 1 cm around the prostate is 
added to account for these uncertainties. The actual radiotherapy treatment is then delivered 
during 7 or 8 weeks in up to 39 fractions of 2 Gray (Gy) in our institute.
erectile dysfunction after radiotheraPy
All forms of treatment for prostate cancer, radiotherapy, prostatectomy and hormonal therapy, 
have an impact on sexual functioning and especially on erectile function (3-5). Because there 
is no clear evidence showing a survival benefit for one treatment above another (6), differ-
ences in quality of life after treatment, including sexual function, might influence the choice 
of treatment. A patient must be informed about the consequences of different treatments to 
enable the patient to make a rational choice.
Since the introduction of three-dimensional external beam radiotherapy, a large number 
of prospective studies analyzed what is called ‘genito-urinary’ toxicity after radiotherapy. Al-
though erectile dysfunction is a common complication only a few prospective studies report 
on the ‘genito’ part of genito-urinary toxicity. However, most of these studies were hampered 
by the lack of questionnaires, inadequate follow-up, no exclusion of hormonal therapy or no 
information about the use of potency aids (7-13).
There are three essential anatomical structures in the vicinity of the prostate to achieve 
and maintain an erection. First of all, cavernous nerves, originating from the neurovascular 
bundles supply the penis with nitric oxide (NO) to start an erection (14). Secondly, the arterial 
flow through the internal pudendal arteries into the penis increases. The third structure is 
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formed by the corpora cavernosa, which ensure adequate trapping of blood to build up pres-
sure (known as the veno-occlusive mechanism) (15).
Figure 1 shows a figure from McLaughlin et al. (16) displaying the basic anatomy in the 
vicinity of the prostate, including three nerve and vascular pathways. The posterior lateral 
pathway includes the neurovascular bundles, while the inferior lateral pathway includes the 
internal pudendal artery. (The anterior inferior pathway includes the dorsal venous complex).
Figure 1. Basic anatomy in the vicinity of the prostate including nerve and vascular pathways.
GU diaphragm = genitourinary diaphragm.
(By the courtesy of Patrick W. McLaughlin).
PreventinG erectile dysfunction
There are two strategies to reduce the risk of erectile dysfunction after radiotherapy for 
prostate cancer. The first strategy is to find an anatomical structure that is responsible for 
erectile dysfunction. If such a structure is found treatment plans can be adjusted so that this 
structure is spared. The second strategy is to reduce the treatment margin, by minimizing 
one or more of the uncertainties for which the treatment margin is needed. If the treatment 
margin is reduced, all structures including those essential for a penile erection will receive a 
lower radiation dose.
The anatomical structure that is responsible for erectile dysfunction after radiotherapy 
might be found by analyzing the correlation between the radiation dose that is received by 
Introduction
11
that structure and whether or not erectile dysfunction has occurred. The corpora cavernosa 
and penile bulb can be easily seen on the planning CT scan and the radiation received by 
them can be analyzed. Although most studies have insufficient follow-up, are retrospective in 
nature or lack statistical power, some authors have already advised to spare the penile bulb 
(17-22). However, according to Dean and Lue the corpus spongiosum, which includes the pe-
nile bulb, is not essential during an erection. The corpus spongiosum only builds up one third 
to one half of the pressure of that in the corpora cavernosa, because it has minimal venous 
occlusion (15). If sparing of the penile bulb is achieved at the cost of reducing the margin 
around the apex, which often contains cancer cells, an oncological risk is taken (23-25). It is 
important to critically review all available literature on this topic and consider the alternatives, 
before one changes the clinical treatment.
Several studies have analyzed the neurovascular bundles and have not found any cor-
relation between the radiation dose in the neurovascular bundles and erectile dysfunction 
after radiotherapy (26-30). The neurovascular bundles are in close proximity to the prostate. 
Therefore it would be difficult to completely spare the neurovascular bundles without losing 
target coverage. However, it is possible to reduce the volume of the neurovascular bundles 
that receives the full radiation dose.
So far only one study has analyzed the correlation between the radiation dose in the 
corpora cavernosa and erectile dysfunction after external beam radiotherapy (31). This ret-
rospective study only analyzed 28 patients, making its conclusion disputable. The corpora 
cavernosa seem a likely structure to be responsible for erectile dysfunction after radiotherapy 
for prostate cancer. Several studies have concluded that the arterial blood flow in the caver-
nosal arteries is decreased in patients with erectile dysfunction after radiotherapy for prostate 
cancer (32-34).
Besides clinical studies, the structures potentially involved in erectile dysfunction after 
radiotherapy can also be investigated by animal experimental studies. The advantage of such 
an approach is that an actual histological analysis of the radiation damage to the different 
structures can be performed. So far, only two studies have used this approach with rats. 
Those two studies used one single fraction of radiation, while in the clinical treatment all 
patients are treated with multiple fractions. Development of a rat model treated with multiple 
fractions will also allow the evaluation of pharmacons that stimulate the arterial flow in the 
penis. Several studies, mostly animal experimental studies, have suggested that the use of 
such pharmacons might help in the recovery of erectile function after nerve-sparing pros-
tatectomy (35). However, there are no reports available on the use of such pharmacons after 
radiotherapy for prostate cancer.
The second strategy to reduce the risk of erectile dysfunction is the reduction of the treat-
ment margin around the prostate. If the treatment margin can be reduced, all structures 
around the prostate, including those responsible for erectile dysfunction, will receive a 
lower radiation dose. A treatment margin accounts for uncertainties regarding delineation, 
Chapter 1
12
deformation and movement. By reducing one or more of those uncertainties the treatment 
margin can be reduced without compromising target coverage. 
The uncertainty of movement can be reduced by implanting gold cylinders, fiducial 
markers, into the prostate. Figure 2 shows an example of these fiducial gold markers. In the 
planning CT scan the positions of the fiducial markers can be correlated to the contours of 
the prostate. Before each treatment fraction the fiducial markers can be imaged from two 
orthogonal angles. This will give a precise location of the prostate. If the treatment couch is 
then shifted to accurately place the prostate at its intended position, there is a possibility to 
reduce the treatment margin.
Although this method allows improvement in positioning of the prostate, information 
about deformation of the prostate relative to the fiducial markers is required before a new, 
reduced treatment margin can be calculated. The deformation can be quantified by using 
repeat CT scans of prostate cancer patients with implanted fiducial markers. This information 
is then used to calculate a new smaller treatment margin, which reduces the radiation dose in 
all structures surrounding the prostate, including those responsible for erectile dysfunction.
Figure 2 shows three fiducial gold markers used for implantation in the prostate. The markers are 1 mm in diameter and 5 mm in length.
scoPe of this thesis
The general scope of this thesis is to find causes of radiation-induced erectile dysfunction 
and feasible methods to prevent erectile dysfunction after external beam radiotherapy for 
prostate cancer.
First it must be assessed whether prostate cancer patients are sexually active and to what 
extent external beam radiotherapy for prostate cancer causes erectile dysfunction (Chapter 2).
If the radiotherapy causes erectile dysfunction, certain anatomical structures must be in-
volved in this process. A critical review of all studies on this topic is performed, to conclude 
whether or not treatment plans should already be adapted to avoid a specific structure (Chap-
ter 3).
There are no prospective studies investigating the correlation between erectile dysfunc-
tion after external beam radiotherapy and the radiation dose to the corpora cavernosa, while 
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several studies found a decreased flow in the cavernosal arteries after radiotherapy (32-34). 
This thesis reports on the first prospective study published on this subject (Chapter 4).
Animal experimental studies allow a histological analysis of the effects of radiotherapy to 
the prostatic area. A pilot study is performed to analyze the impact of fractionated irradiation 
of the prostate on the penile arteries of the rat (Chapter 5).
Besides finding a specific structure that is responsible for erectile dysfunction, it is also 
possible to reduce the treatment margin. If the treatment margin is reduced, all structures 
including those essential for an erection will receive a lower radiation dose. 
A method called stereographic targeting was developed in our institute. Stereographic 
targeting is a procedure for daily positioning corrections of the prostate based on implanted 
fiducial markers, which allows a reduction of the treatment margin without losing target cov-
erage (Chapter 6).
However, before such a margin can be calculated, the deformation of the prostate relative 
to the fiducial markers must be quantified. A study was performed in which patients were 
implanted with fiducial markers, after which the deformation was analyzed with repeat CT 
scans using deformable registration (Chapter 7). 
In the Discussion and Conclusion, the studies in this thesis and the ongoing studies are put 
in a broader perspective and a final conclusion is drawn (Chapter 8).
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abstract
Purpose 
The purpose of this study is to provide information about sexual function (SF) after three-
dimensional conformal radiotherapy (3D-CRT) for prostate cancer while taking important 
factors into account that influence SF.
Methods and Materials
Between June 1997 and February 2003, a total of 268 patients from a randomized dose-
escalation trial comparing 68 Gy and 78 Gy agreed to participate in an additional part of the 
trial that evaluated SF.
Results
At baseline 28% of patients had erectile dysfunction (ED). After 1 year, 27% of the pretreatment 
potent patients had developed ED. After 2 years this percentage had increased to 36%. After 
3 years it almost stabilized at 38%. Satisfaction with sexual life was significantly correlated 
with ED. After 2 years one third of the pre-treatment potent patients still had considerable to 
very much sexual desire and found sex (very) important. No significant differences were found 
between the two dose-arms. Potency aids were used on a regular base by 14% of the patients.
Conclusion
By taking adjuvant hormonal therapy (HT), HT during follow-up and potency aids into ac-
count, we found a lower percentage of ED after 3D-CRT than reported in previous prospective 
studies. A large group of patients still had sexual desire, considered sex important and 14% 
used potency aids after 3D-CRT.
Sexual function after 3D-CRT for prostate cancer
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introduction
Prostate cancer is the most common type of cancer in men in Western countries with the 
exception of basal and squamous cell skin cancers (36). There are several treatment modalities 
for prostate cancer: radical prostatectomy, external beam radiotherapy, brachytherapy, and 
hormonal therapy (HT). Because there is no clear evidence showing a survival benefit for any 
of these therapies above another (6), quality of life after treatment, including sexual function 
(SF), should influence the choice of treatment. Reliable information about the consequences 
of different types of treatment should be provided to all patients, to enable them to make 
a more rational choice of therapy. A decrease in SF is a common side effect in all forms of 
treatment for prostate cancer and is associated with impaired quality of life (37,38). Since 
the introduction of three-dimensional conformal radiotherapy (3D-CRT), several prospective 
studies have provided reliable information about health-related quality of life after such treat-
ment for prostate cancer. Most studies have concentrated on gastro-intestinal and genito-
urinary toxicity. Less attention has been paid to SF. Studies reporting on SF after 3D-CRT have 
focused primarily on erectile dysfunction (ED), whereas sexual interest, pleasure, and activity 
are a significant part of SF as well. Limitations in prospective studies to the effect of 3D-CRT 
on ED have led to a large difference in reported ED rates, varying from 7% to 59% (7-11). 
Physician documented ED provides one of those limitations. Physicians tend to underestimate 
symptoms causing health related quality of life impairment (39). One study, using physician 
documented ED, reported a remarkably low percentage of post-irradiation ED of only 7% (8). 
On the other hand, patient documented ED by means of questionnaires provides more reli-
able results (39). Some studies were not designed with an objective to provide an accurate 
ED rate. These studies did not have an adequate follow-up period of at least 18 months with 
a sufficient number of patients (7,9). The time elapsed between 3D-CRT and ED evaluation is 
important as one should wait at least 18 to 24 months when ED occurrence reaches a maxi-
mum and remains stable further on (40). There are three more important factors that must be 
considered when evaluating SF. These factors are adjuvant HT, HT during follow-up because of 
biochemical or clinical relapse and the use of potency aids, like phosphodiesterase-5 (PDE5) 
inhibitors, intracavernosal injections (ICI), penis rings, and vacuum devices. So far, prospective 
studies reporting on SF after 3D-CRT did not take all of these factors into account (7-11). 
The purpose of this present study is to report on the effect of 3D-CRT not only on erectile 
function but on other domains of SF as well, taking important factors into account that influ-
ence SF like adjuvant HT, HT during follow-up and potency aids.
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methods and materials
Our center coordinated a Dutch multicenter Phase III dose-escalation trial (trial code CKVO 
96-10), in which patients with a localized adenocarcinoma of the prostate were randomized 
between prescribed dose levels of 68 Gy and 78 Gy. In our center 404 patients were included 
in this trial. All of them were asked to participate in an additional part of the trial in which 
quality of life and SF would also be evaluated. Between June 1997 and February 2003, 268 
patients agreed to participate in the additional part of the trial in which SF would be evalu-
ated. Forty-five patients were excluded because they did not fill out the questionnaire on SF 
within 30 days after trial registration. There is evidence that adjuvant HT (11), as well as HT as 
monotherapy (3), has a significant impact on SF. Because of treatment with adjuvant HT 29 
patients were excluded from analysis, unless stated otherwise. Furthermore, patients who had 
a relapse were censored at the time of relapse. A relapse was defined as: biochemical relapse 
according to the ASTRO definition of 1996 (41), clinical relapse, or the start of therapy such as 
HT during follow-up or salvage therapy, which ever comes first. 
Radiotherapy
The details of the dose-escalation trial have been described extensively before (42). Briefly, 
dose–volume groups were defined according to the risk of involvement of the seminal vesi-
cles, according to Partin et al. (43). Patients with a T1b, T1c, and T2a prostate cancer with a risk 
of involvement of <10%, 10%–25%, and >25% were included in dose–volume Groups 1, 2, and 
3, respectively. All patients with a T2b and T3a were treated in Group 3. Group 4 comprised all 
patients with a T3b or T4. For each dose–volume group, specific planning target volumes were 
defined. For dose–volume Groups 1 and 4, the clinical target volumes (CTVs) were defined 
as the prostate only and as the prostate with seminal vesicles, respectively. In dose–volume 
Groups 2 and 3, the seminal vesicles were excluded from the CTV after 50 Gy and 68 Gy, re-
spectively. For all patients, a margin of 10 mm was added to the CTV to obtain the planning 
target volume for the first 68 Gy, and this margin was reduced to 5 mm (except toward the 
rectum where no margin was taken) for the last 10 Gy in the 78 Gy arm. In our center 3D-CRT 
was used with a 3-field technique using one anterior and two lateral wedged fields. In the high 
treatment arm a boost of 10 Gy was given with the same technique. The dose was specified to 
the ICRU reference point (2) and was delivered in fractions of 2 Gy. Treatment with adjuvant 
HT, duration and type of adjuvant HT was left to the discretion of the referring physician.
Sexual function
The SF was assessed with the Dutch module on sexual activity (SAc) consisting of 10 single 
items that do not add up to a scale (44). Sexual activity was defined as masturbation or inter-
course. Each item contains three to five answer categories. A skip pattern enables differen-
tiating in sexually active vs. inactive men. Sexually inactive men were asked why they were 
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inactive (no desire; no partner; partner had no desire; ED or other reasons), while sexually 
active men were asked whether ED (problems with achieving or maintaining erections) had 
occurred. Other items assessed spontaneous erections (not during sexual activity), desire, 
satisfaction with SF and importance of sex. Six retrospective questions were added to the 
SAc to assess the influence of the diagnosis of prostate cancer on SF. A copy of the complete 
questionnaire has been included in a previous article (45). ED was defined as (almost) always 
having problems in achieving or maintaining an erection if wished to, or not being sexually 
active because of erectile problems. The questionnaire was given to the patient at baseline 
and at 6 months, 1, 2, and 3 years after the start of 3D-CRT. The number of patients per item 
may fluctuate due to the fact that not all patients answered every question. 
The study was designed before the introduction of oral PDE5-inhibitors, so no assessment 
of potency aids was done. Therefore a questionnaire was developed to retrospectively assess 
the use of potency aids: PDE5- inhibitors, ICI, intraurethral alprostadil, vacuum devices and/
or a penisring. In June 2006 this questionnaire was sent to all patients, including those who 
used adjuvant HT, with at least 2 years of follow-up who did not have ED at baseline and who 
were alive at the moment the questionnaire was sent. The patients were asked 3 questions: 
Whether they had used potency aids on a regular base before 3D-CRT, during the first 2 years 
after 3D-CRT and/or after more then 2 years after 3D-CRT. Patients could answer “yes” or “no.” 
When answering “yes” they were asked to make a choice between different kinds of potency 
aids. 
Statistical Analysis
The statistical analysis was primarily descriptive. Differences between patient characteristics 
were tested with the Kruskal-Wallis and the Pearson Chi-square test. Correlation between ED 
and spontaneous erections was tested with the Pearson Chi-square test. Correlation between 
satisfaction with sexual life and ED was tested with the Kruskal-Wallis test. A separate analysis 
was performed to assess the correlation between being sexually active and adjuvant HT. Dif-
ferences in being sexually active were tested with the Pearson Chi-square test.
results
Impact of the diagnosis of prostate cancer
Of the patients, 59% (114/192) recalled being sexually active before the diagnosis of prostate 
cancer. For the sexually active patients the diagnosis of cancer led to an important decrease 
in sexual activity in 33% (37/113), in sexual interest in 29% (33/113), in sexual pleasure in 18% 
(20/111); and there was an increase in problems achieving and/or maintaining an erection in 
29% (32/111). In the 2 weeks before filling out the baseline questionnaire 52% (101/194) of 
the patients were sexually active.
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Sexual function at baseline
Fifty-five out of 194 patients (28%) already had ED at baseline (Fig. 1). Of these 55 patients, 
15 (27%) reported having always had problems with achieving and/or maintaining an erec-
tion but remained sexually active, either by masturbation or intercourse. All but one of these 
patients described their erection quality as semi rigid to flaccid. Of all patient characteristics 
only cardiovascular history was significantly correlated with ED at baseline (p = 0.02) (Table 1). 
Furthermore 38% (53/139) of the patients who did not have ED, were not sexually active. Pa-
tients were allowed to give more than one answer to the question why they were not sexually 
active. The most common reasons were: no desire in 55% (29/53) and no partner or a partner 
without desire in 26% (19/53).












Figure 1. Erectile dysfunction (ED) and sexual activity at baseline
Characteristics ED at baseline No ED at baseline
both arms (%) both arms (%) 68 Gy (%) 78 Gy (%)
Number of patients 55 139 66 73
Mean follow-up, months
Median age, years
31
70
27
68
27
68
28
68
Mean PSA, μg/L 14.5 13.0 12.7 13.2
T-stage ≥ T3 13/53 (25) 44/137 (32) 21/64 (33) 23/73 (32)
Gleasonscore ≥ 7 18/47 (38) 64/118 (54) 30/57 (53) 34/61 (56)
Diabetes Mellitus 4/55 (7) 4/139 (3) 2/66 (3) 2/73 (3)
Cardiovascular history 23/55 (42)* 35/139 (25)* 18/66 (27) 17/73 (23)
Table 1. Patient characteristics at baseline. The characteristics for patients with and without erectile dysfunction (ED) are shown separately. The 
characteristics for the standard arm (68 Gy) and the dose escalation arm (78 Gy) of the patients without ED are also shown separately.
PSA = prostate specific antigen
* p=0.02 Pearson chi-square test to compare patients with and without ED at baseline
Impact of radiotherapy
To assess the impact of 3D-CRT on SF, 55 patients of the 194 were excluded because they al-
ready had ED at baseline, leaving 139 patients for this analysis. After 1 year 27% of the patients 
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had developed ED (Fig. 2a). After 2 years this percentage had increased to 36%, after which 
the percentage of ED almost stabilized. After 3 years 38% of the patients had ED. Most of the 
patients suffering from ED after 2 years (20/35) were still sexually active. Despite the fact that 
they (almost) always had problems with achieving or maintaining an erection, they were still 
able to have intercourse or masturbate. All of these patients but one described the quality of 
erection as semi rigid to flaccid. There was a decline in sexual activity from 62% at baseline to 
51% 2 years after 3D-CRT (Fig. 2b). 
Of the patients, 29 were still sexually active and had not developed ED 2 years after 3D-
CRT. Although they did not develop ED, 48% (13/27) of those patients did have a decline in 
erectile function. They had more problems with achieving (7/27) and/or maintaining (8/27) an 
erection and/or had a decline in the quality of erection (10/27) compared with their baseline.
There was a decrease in having spontaneous erections (not during sexual activity) from 
70% (95/136) at baseline to 47% (46/97) after 2 years. Absence of spontaneous erections was 
significantly correlated with ED 2 years after 3D-CRT (p < 0.01). The percentage of patients in-
dicating to have considerable to very much desire became slightly lower from 41% (56/136) at 
baseline to 32% (31/96) after 2 years. This was comparable for patients finding sex important 
or very important. At baseline 40% (55/137) of the patients found sex (very) important. After 2 
years this percentage was 31% (30/97). At baseline 54% (73/134) of the patients were satisfied 
or very satisfied with their sexual lives, which was slightly lower after 2 years, 45% (42/94). Sat-
isfaction with sexual life was significantly correlated to ED 2 years after 3D-CRT (p < 0.01). No 
statistically significant differences in ED, sexual activity, spontaneous erections, sexual desire, 
importance of sex or satisfaction with sexual life were found between the standard arm (68 
Gy) and the dose-escalation arm (78 Gy) at 1, 2, and 3 years after 3D-CRT.
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Figure 2. Percentage of patients with erectile dysfunction (ED) (A) and sexually active patients (B) at baseline and after three-dimensional 
conformal radiotherapy (3D-CRT). Patients with ED at baseline are excluded. The total number of patients (n) is shown under each bar. Differences 
in ED and sexual activity between the standard arm (68 Gy) and the dose escalation arm (78 Gy) were compared (Pearson Chi-square test). No 
significant differences were found.
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Hormonal therapy
Twenty-nine patients were treated with adjuvant HT. This group of patients did not differ 
significantly from the group who did not receive adjuvant HT with respect to randomization 
arm (p = 0.89), Gleason score (p = 0.17), diabetes (p = 0.27), or cardiovascular history (p = 
0.16). The mean age of patients treated with adjuvant HT was lower, 66 vs. 68 years, but this 
difference was not significant (p = 0.10). Patients treated with adjuvant HT had a significantly 
higher T-stage (p < 0.01) and a significantly higher mean PSA (p < 0.01). Significantly more 
patients treated with adjuvant HT were sexually active before diagnosis (Fig. 3). Adjuvant HT 
was started before the baseline questionnaire was filled out, and at baseline, the difference in 
sexual activity between the two groups was no longer significant. One year after 3D-CRT sig-
nificantly less patients treated with adjuvant HT were sexually active. The difference between 
the 2 groups remained almost the same at 2 and 3 years after 3D-CRT, but the number of pa-
tients was less. So no statistically significant difference was found 2 and 3 years after 3D-CRT.
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Figure 3. Percentages of sexually active patients treated with and without adjuvant hormonal therapy (HT) before diagnosis (BD) and at each 
year after three- dimensional conformal radiotherapy (3D-CRT). The total number of patients (n=) is shown under each bar. Differences in sexual 
activity between patients treated with and without adjuvant HT were compared (Pearson Chi-square test). Values of p < 0.05 are shown.
Potency aids
The questionnaire assessing the use of potency aids was sent to all patients with at least 2 
years of follow-up who did not have ED at baseline. In this case the questionnaire was also 
sent to patients who were treated with adjuvant HT. Seventeen patients were deceased and 
the addresses of three patients could not be retrieved. Questionnaires were sent to 91 pa-
tients of whom 81 patients responded (89%). Only one patient already used ICI before 3D-CRT 
and continued using it after 3D-CRT. Six patients started using oral PDE5-inhibitors within 2 
years after 3D-CRT. Only one of these patients indicated not to have ED during follow-up in 
the SAc. He added the statement that he did have ED when not using a PDE5 inhibitor. None 
of the patients reported use of vacuum devices or urethral alprostadil. After more than 2 years 
after 3D-CRT 14% (11/81) of the patients used potency aids on a regular base.
p=0.039
p=0.037
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discussion
Several studies, including one randomized controlled trial with HT as monotherapy, reported 
that HT has a significant impact on SF (3,11,46). Zelefsky et al. (11) reported that neoadjuvant 
HT increased the risk of ED even 5 years after 3D-CRT. Chen et al. (9) reported however that 
adjuvant HT did not appear to have an impact on SF after 3D-CRT. Our study showed a sig-
nificant correlation with adjuvant HT and sexual activity. We believe that excluding patients 
treated with adjuvant HT will lead to a more precise assessment of the impact of 3D-CRT 
on SF. Potosky et al. (46) reported that HT as monotherapy not only has a significant impact 
on being sexually active, but also impacts libido and erectile function. In the present study 
the retrospective questions assessing sexual desire and erectile function before the start of 
adjuvant HT could not be compared with prospective questions during follow-up. Patients 
treated with HT during follow-up were censored at the start of HT. Therefore the effect of HT 
during follow-up on SF could not be analyzed in this study. A Kaplan-Meier plot in the study 
from Borghede et al. (8) did show that HT during follow-up after 3D-CRT has an impact on 
potency, although no statistical analysis was performed.
Most patients using potency aids reported ED in the SAc. Only one indicated no ED. There-
fore the use of potency aids did not have an important influence on the percentage of ED 
in this study. Excluding patients, using potency aids, from this analysis would lead to a false 
low percentage of ED. Several validated questionnaires that assessed SF were available when 
this study was designed (47-51). However, no validated Dutch translations of those question-
naires were available at the moment of study design, but there was experience with the SAc 
in several studies (45,52,53). The SAc has been evaluated by Korfage et al. (44). The SAc has 
some advantages compared with the International Index of Erectile Function (IIEF) question-
naire (54). A large part of the IIEF questionnaire regards questions on sexual intercourse with 
penetration. Therefore the IIEF questionnaire is not suitable for homosexual men, patients 
without a sexually active partner or patients without a partner.
The diagnosis of prostate cancer resulted in a decrease in SF, although it must be consid-
ered that SF before diagnosis was assessed retrospectively. This agrees with a previous study 
from Incrocci et al. (45). Korfage et al. (55) reported the results of a prospective study on the 
impact of diagnosis on the patient’s quality of life. Assessment of quality of life in a large 
group of patients who were about to be screened for prostate cancer was performed. In the 
men, who were diagnosed with prostate cancer, quality of life 2 months before diagnosis was 
compared with quality of life 1 month after diagnosis. diagnosis of prostate cancer led to a 
significant decline in quality of life (55).
So far the focus of studies on SF after 3D-CRT has been on ED. This study reports on sexual 
activity as well. A large percentage of the men with ED remained sexually active (20/35), even 
though almost all of the patients indicated to have a semirigid to flaccid penis during sexual 
activity. This raises the interesting question whether patients who have ED after 3D-CRT, might 
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remain sexually active by means of masturbation or oral sex, if their erection is insufficient for 
intercourse. To our knowledge this question has not been answered yet.
Zelefsky et al. (11) reported about a large group of 743 patients. Potency was defined as 
the ability to achieve an erection adequate for penetration. Of the patients, 27% were impo-
tent before treatment, which is comparable to our 28%. The 5-year actuarial likelihood risk 
of potency loss was 60%. A significant difference was found between the 5-year actuarial 
likelihood risk of potency loss of 69% in patients treated with neoadjuvant HT and 56% in 
patients treated with 3D-CRT alone. The 5-year actuarial likelihood risk of 56% is higher then 
the ED rate in the present study of 38% after 3 years. Although a different definition for ED 
was used, there are other reasons as well that may explain why their rate of ED was higher. It 
is unclear whether patients treated with HT during follow-up were censored at the start of HT 
(11). Another difference is the longer follow-up period in their study. Although several studies 
that censored patients at the start of HT in follow-up, including the present study, report that 
the ED rate stabilizes after 2 years (8,10), a Kaplan-Meier plot in the study from Borghede et al. 
(8) clearly showed an increase in ED rates after 2 years only in patients treated with HT during 
follow-up.
Turner et al. (10) reported on a group of 290 patients. Total impotence was defined as the 
inability to achieve an erection at all or an inability to ever maintain an erection adequate 
for intercourse. Forty-seven patients with adjuvant HT were identified, but they were not 
excluded from analysis. Thirty-nine patients treated with HT during follow-up were censored 
at the start of HT. The baseline ED rate of 37% was higher then our 28%. Again, a different 
definition was used, but another explanation might be the fact that 16% of the patients were 
treated with adjuvant HT, but were not excluded from the analysis. The percentage of total 
impotence at 2 years after 3D-CRT was 59%. This percentage is higher than our 36% of ED at 
2 years after 3D-CRT. Zelefsky et al. (11) reported that neoadjuvant HT leads to a significant 
higher percentage of ED. Furthermore only one third of the potent patients at baseline had 
a sufficient follow-up of 2 years. So compliance in follow-up was low. These two factors, next 
to the use of another definition, may contribute to the difference between the ED rate of 59% 
form the Turner study (10) and the 36% of the present study.
Zelefsky et al. (11) were the first to report that a higher radiation dose is significantly cor-
related with a higher incidence of ED after 3D-CRT. We did not find this correlation in our 
study. Although differences were seen in sexual activity between the standard arm and the 
dose-escalation arm, these differences were not statistically significant. Between our report 
and the report by Zelefsky et al. (11), there are two differences concerning the correlation 
between dose-escalation and ED. Zelefsky et al. (11) had a larger patient group. Furthermore, 
our report presents the results from a randomized dose-escalation trial, whereas the report 
of Zelefsky et al. (11) is based on a study in which the treatment with different dose levels 
was done sequentially during 7 years. Little et al. (56) did not find a difference in ED in their 
randomized dose escalation trial of 70 Gy vs. 78 Gy. Their group of 211 patients was smaller 
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than the patient group of Zelefsky et al. (11) and assessment of SF at baseline was done 
retrospectively. Furthermore the patients in the 70 Gy arm were treated with conventional 
radiotherapy, whereas the patients in the 78 Gy arm were treated with 3D-CRT for the last 16 
fractions of 2 Gy. Given the contradictory data concerning the role of dose-escalation in ED 
after 3D-CRT, we believe that more research is needed to come to a final conclusion.
conclusion
Previous prospective studies on the effect of 3D-CRT on SF may not have excluded all pa-
tients treated with adjuvant HT and censored patients treated with HT during follow-up at the 
start of HT. Therefore they might have given an overestimation of the rate of ED after 3D-CRT 
(10,11). We found an ED percentage of 36% 2 years after the start of 3D-CRT. We did not find a 
difference in ED between the two dose levels (68 Gy vs. 78 Gy). Two years after 3D-CRT almost 
half of the sexually active men who did not develop ED did have a decline in erectile function, 
about one third of the patients still had considerable to very much sexual desire and one third 
found sex (very) important. Potency aids were used regularly by 14% of the patients. Lower 
satisfaction with sexual life was significantly correlated with development of ED. Finding new 
techniques to lower the prevalence of ED after 3D-CRT for prostate cancer, has a great poten-
tial to improve the quality of life after treatment.

Chapter 3
Erectile dysfunction after radiotherapy for 
prostate cancer and radiation dose to the 
penile structures: a critical review
Gerard J. van der Wielen
John P. Mulhall
Luca Incrocci
Radiother Oncol 2007;84:107-113
Chapter 3
28
abstract
Erectile dysfunction (ED) is a common sequela after external beam radiotherapy and brachy-
therapy for prostate cancer. There are several structures in the vicinity of the prostate that are 
critical to erectile function and that receive a substantial radiation dose: neurovascular bun-
dles (NVBs), internal pudendal arteries (IPAs), accessory pudendal arteries, corpora cavernosa 
and the penile bulb. Most reports analyzing the correlation between radiation dose to these 
structures and radiation-induced ED are limited by the small number of patients analyzed in 
each study. So far, there is no evidence for a role of the NVBs in radiation-induced ED. There are 
no reports on the IPAs, based on reduced arterial flow in the penis. Several studies show con-
tradicting results on the corpora cavernosa, which house the erectile tissue required for erec-
tion. There are contradicting reports on the penile bulb, although studies with more patients 
tend not to find any correlation. Sparing of the penile bulb to improve potency-preservation 
is not sufficiently supported by the current literature. If sparing of the penile bulb is achieved 
by reducing the margin for the apex, an oncological risk is taken, while it is uncertain whether 
this will improve potency-preservation.
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introduction
There are three major requirements for adequate penile erection (i) functioning cavernous 
nerves which supply the penis with nitric oxide (NO) (14) (ii) arterial inflow through the in-
ternal pudendal or accessory pudendal arteries and (iii) healthy erectile tissue which ensures 
adequate trapping of blood in the penis to maintain erection (known as the venocclusive 
mechanism) (15). The corpora cavernosa which house the erectile tissue (composed predomi-
nantly of smooth muscle, collagen and endothelium) are paired structures which are joined by 
a septum as they lie within the external penis. These structures diverge as the urethra passes 
cephalad into the bladder and each passes underneath its respective ischiopubic ramus (Fig. 
1A). The corpus spongiosum, which is strictly speaking not an erectile body, surrounds the 
urethra. At the point of divergence of the corpora cavernosa the spongiosum is known as 
the bulb (Fig. 1B). Thus, the aforementioned anatomic structures are in close proximity to 
the prostate and the field of radiation. Erectile dysfunction (ED) is one of the most common 
sequelae of radiotherapy for prostate cancer, affecting 36–59% of patients after external 
beam radiotherapy (EBRT) (5,10,11) and 24–50% after brachytherapy (BT) (57-59) according 
to prospective studies.
Understanding the anatomic structures responsible for radiation-induced ED will enable 
radiation oncologists to avoid delivery of a high radiation dose to those structures. DiBiase 
et al. (26) were the first to investigate this area. Since then many reports on this subject have 
followed. The purpose of this review is to provide a critical overview of these reports. 
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Figure 1. (a) The penile bulb (PB), the corpora cavernosa (CC) and the crura (crus) on a CT can. (b) The penile bulb is continuous with the rest of 
the corpus spongiosum (CS) in a more caudal CT slice.
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materials and methods
On June 18, 2007 a systematic search for published articles was performed using the electron-
ic database PubMed. The following search terms were included erectile, penile, bulb, crura, 
crus, cavernosa, cavernous or neurovascular in combination with the search term prostate 
and the search terms radiation, radiotherapy, brachytherapy or implantation. There was no 
limit applied on publication year, language or study design. All articles providing data on the 
correlation between erectile dysfunction after radiotherapy and the radiation dose in specific 
structures, other than the prostate, were selected. Further articles were found by scanning 
reference lists or relevant articles. The selected articles were entered into a database, using 
reference software (Reference Manager).
results
A total of 526 items were found. Of these items 16 were found to be relevant to this review. 
These items consisted of 15 articles and 1 abstract. Only the articles were used for this review, 
because the abstract, by its nature, only provided limited information.
Penile bulb
Most studies have analyzed dose volume effects between radiation dose in the penile bulb 
and ED after BT or EBRT (Table 1) (17-22,27,30,31,57,60,61). However, it should be recognized 
that the penile bulb is not an essential structure in achieving and maintaining an erection 
(62). The penile bulb is the proximal enlargement of the corpus spongiosum. According to 
Dean and Lue (15) the pressure in the corpus spongiosum during erection is only one-third 
to one-half of the pressure in the corpora cavernosa, because there is minimal venous occlu-
sion in the corpus spongiosum. Therefore the rigidity of the penis depends predominantly on 
the corpora cavernosa. While the role of the penile bulb can be questioned, the dose to the 
penile bulb is correlated with the dose in the proximalmost region of the corpora cavernosa, 
the crura, in both EBRT (18,63) and BT (20). It has been suggested that the dose to the penile 
bulb may be a surrogate for the dose in the crura (62). In addition, finding a significant cor-
relation between the radiation dose received by the penile bulb and ED does not mean that 
lowering this dose would result in a decreased incidence of post-radiation ED. It is possible 
that the radiation dose in another structure in the vicinity of the penile bulb is responsible for 
radiation-induced ED, such as the crura, the IPAs, the NVBs or even other anatomic structures.
Several reports (17,19-21,27,60) have failed to give clear information how the penile bulb 
is contoured. Other reports (18,22,30,31,57,61) based the contouring of the penile bulb on 
the report from Wallner et al. (64). Wallner et al. (64) described the anatomic boundaries of the 
penile bulb based on pre- and post-BT CT scans and MRI scans and, transrectal ultrasound. 
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authors year other 
structures
prospective
ED evaluation
n= treatment 
technique
follow-up
in month
significant 
correlation
findings
Fisch et al. 
(17)
2001 no no 21 3D-CRT 24 yes median D70 of the PB 
with a 70 Gy cutpoint
Merrick et al. 
(19)
2001 no no 46 BT mean 35 yes minimum D25, D50, D70, 
D75, D90 and D95 of 
the PB
Merrick et al. 
(20)
2002 crura no 60 BT 26-79 yes minimum D50 of the PB
Merrick et al. 
(57)
2005 crura yes 128 BT 13-42 no minimum D50 of the 
proximal crura.
Kiteley et al. 
(27)
2002 NVB yes 50 BT 24-45 no no significant correlations
Wright et al. 
(30)
2004 NVB, crura no 41 BT 12-41 yes minimum D90 with 
a 10% cutpoint of 
the prescribed dose. 
Paradoxal result in NVB 
analysis 
Selek et al. 
(31)
2004 corpora 
cavernosa
no 28 3D-CRT ≥ 24 no paradoxical result: potent 
patients had a higher 
dose to penile base 
structures
Roach et al. 
(21)
2004 no yes 158 3D-CRT n.a. yes median dose to the 
penile bulb ≥ 52.5 Gy
Wernicke et 
al. (22)
2004 no yes 29 3D-CRT 18-42 yes median dose to D30, D45, 
D60 and D75
MacDonald 
et al. (61)
2005 no yes 226 BT ≥ 24 no no significant correlations
Mangar et al. 
(18)
2006 no yes 51 3D-CRT 24 yes mean D90 with a 
cutpoint of 50 Gy and 
60 Gy
Brown et al. 
(60)
2007 no yes 32 IMRT 24 no no significant correlations
Table 1. Correlation between radiation dose to the penile bulb and radiation-induced erectile dysfunction: Summary of the published studies.
3D-CRT = three dimensional conformal radiotherapy
PB = penile bulb
BT  = brachytherapy
D xx = dose delivered to xx % of an anatomic structure
NVB = neurovascular bundles
n.a. = not available
IMRT = intensity modulated radiotherapy
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Because the penile bulb is continuous with the rest of the corpus spongiosum it is arbitrary 
where the boundary between the penile bulb and the rest of the corpus spongiosum is lo-
cated (Fig. 1B). Two reports (18,31) used the level of the inferiormost aspect of the ischial 
tuberosities to define this boundary. However, this definition leads to a much larger volume, 
as pointed out by Buyyounouski et al. (65), because a part of the corpus spongiosum is in-
cluded as well. 
Several authors (17-22) have advised to spare the penile bulb. There are contradicting 
reports on the role of the penile bulb in radiation-induced ED. Several studies with small num-
bers of patients give results that may not be representative of the whole population, either in 
finding positive or negative correlations. For example, one study (31) with 28 patients found 
the following statistically significant correlation: patients who maintained potency seemed to 
have had more volume irradiated and the penile base structures received a higher radiation 
dose than the patients who had ED after radiotherapy. Two of the three larger studies, with 
more than 60 patients, did not find a correlation between post-radiation ED and the radiation 
dose to the penile bulb (57,61). Furthermore it has to be considered that often carcinoma is 
present in the apex of the prostate. In studies (23-25) analyzing prostatectomy specimen of 
patients after prostatectomy with T1 and T2 tumors, the apex of the prostate was involved in 
most of the cases. If sparing of the penile bulb is achieved by reducing the margin around the 
apex of the prostate, then an oncological risk will be taken, while it is still uncertain whether a 
lower percentage of patients would complain of post-radiation ED. 
Neurovascular bundles 
Radiation dose to the NVBs could be an important factor in understanding ED after radio-
therapy. After radical prostatectomy the extent of the neurovascular bundle preservation 
is predictive of potency recovery (66). The NVBs are only a few millimeters apart from the 
prostate (67) and therefore they receive a high radiation dose (28). So far, only brachytherapy 
studies analyzed the dose in the NVBs (Table 2) (26-30). These studies based the position of 
the NVBs on a model, instead of the actual position, because the NVBs are not visualized on 
CT scans. In four of these studies (26-29) the model determining the position of the NVBs was 
based on an anatomical study of one single cadaver by Lepor et al. (67). More recent studies 
(68-70) showed that the NVBs are much more extensively spread (up to 3 cm anterior–poste-
rior), than the model used to determine the position of the NVBs. Wright et al. (30) based their 
model of the NVBs on the average position of the NVBs of nine randomly selected prostate en-
dorectal coil MRIs. However this model could not take into account inter-individual variation 
in topographic anatomy, which is especially pronounced near the apex of the prostate (70).
DiBiase et al. (26) were the first to report that three patients who had developed ED after 
BT had maximal NVB doses that far exceeded the average values. No statistical analysis was 
performed. The studies (27-30) following this initial report did perform a statistical analysis, 
but could not confirm that suggestion made by DiBiase et al. (26) that the radiation dose to 
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the neurovascular bundles might be correlated to ED after BT. In spite of this, it must be kept 
in mind that statistical power in these studies might not be sufficient. The number of patients 
in these studies was around 50 or less. Furthermore, there is room for improvements in the 
methods used, because none of the studies analyzed the radiation dose in the actual NVBs of 
each individual patient.
In patients who suffer from ED after radical prostatectomy the effectiveness of sildenafil is 
highly dependent on sparing of the NVBs. Zagaja et al. (71) report that sildenafil was ineffec-
tive after non-nerve sparing radical prostatectomy, whereas 33–80%, depending on age of 
the patient, responded to sildenafil after bilateral nerve sparing radical prostatectomy. So, if 
both NVBs are damaged during radical prostatectomy, sildenafil is ineffective. However, silde-
nafil is effective for ED after radiotherapy in half of the patients (72,73). Therefore it is unlikely 
that ED after radiotherapy can be fully explained by damage to the NVBs. Even if radiation to 
the NVBs is the main cause of ED after radiotherapy, it still would be questionable whether it 
is possible to spare the NVBs, because of their close proximity to the prostate.
authors year other 
structures
prospective 
ED 
evaluation
n= treatment 
technique
follow-up
in month
significant 
correlation
findings
DiBiase et al. 
(26)
2000 no no 14 BT n.a. n.a. Maximal NVB doses 
exceeded average values in 
3 patients with postimplant 
impotence
Merrick et al. 
(28)
2000 no yes 54 BT median 
37
no no significant correlations
Merrick et al. 
(29)
2001 no yes 34 BT median 
13
no no significant correlations
Kiteley et al. 
(27)
2002 penile 
bulb
yes 50 BT 24-45 no no significant correlations
Wright et al. 
(30)
2004 penile 
bulb, 
crura
no 41 BT 12-41 no paradoxal result: decreased 
ED risk with a higher dose 
to the right NVB 
Table 2. Correlation between radiation dose to the neurovascular bundle and radiation-induced erectile dysfunction: Summary of the published studies.
BT = brachytherapy
NVB = neurovascular bundle
ED = erectile dysfunction
Crura
In the penis the two corpora cavernosa lie side by side to each other. More posteriorly in the 
perineum the two corpora cavernosa separate and form the crura of the penis (64). The crura 
receive a substantial radiation dose during radiotherapy for prostate cancer, especially during 
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EBRT (63) and to a lesser extent during BT (20,30). Several studies have tried to elucidate the 
etiology of ED after radiotherapy by using Doppler ultrasound (32-34). These studies demon-
strated a reduced flow in the cavernosal arteries and venous leakage of the corpora cavernosa 
in men with ED after radiotherapy. The study populations consisted mainly of EBRT patients. 
Carrier et al. (74) reported that rats irradiated at the prostatic area had a significant decrease 
in number of nitric oxide synthase-containing fibers in the corpora cavernosa. Nitric oxide is 
an important mediator of erection (14). 
Two BT studies analyzed the proximal first and subsequent three centimeters of the crura 
(Table 3) (20,57). Another BT study analyzed the whole crura (30). While the only EBRT study 
contoured the corpora cavernosa until the most inferior aspect of the ischial tuberosities (31). 
Buyyounouski et al. (65) pointed out that contouring this larger part of the corpora cavernosa 
made it increasingly difficult to find statistical significance. Only the first centimeter received a 
high radiation dose (62). Contouring a larger part will lead to a large low dose volume. This will 
probably make the differences between the groups smaller. Although the corpora cavernosa 
seem a logical structure to be involved in radiation-induced ED, only one of the four studies 
(57) found a significant correlation between the dose in the crura and ED after radiotherapy. 
It should be considered, however, that the positive correlation study comprised a much larger 
number of patients than the studies that did not find a significant correlation. Lack of statisti-
authors year other 
structures
prospective 
ED 
evaluation
n= treatment 
technique
follow-up
in month
significant 
correlation
findings
Merrick et al. 
(20) 
2002 penile 
bulb
no 60 BT 26-79 no minimum D50 of the 
penile bulb
Merrick et al. 
(57)
2005 penile 
bulb
yes 128 BT 13-42 yes minimum D50 of the 
proximal crura
Wright et al. 
(30)
2004 penile 
bulb, NVB
no 41 BT 12-41 no no significant correlation
Selek et al. (31) 2004 corpora 
cavernosa
no 28 3D-CRT 24 no potent patients more 
volume irradiated at a 
higher dose to penile base 
structures
Table 3. Correlation between radiation dose to the corpora cavernosa or crura and radiation-induced erectile dysfunction: Summary of the 
published studies.
BT = brachytherapy
D xx = dose delivered to xx % of an anatomic structure
NVB = neurovascular bundle
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cal power might be the reason that these other studies (20,30,31) did not find a significant 
correlation. 
Internal pudendal arteries
The reduced flow in the cavernosal arteries in patients with ED after radiotherapy for prostate 
cancer demonstrated by several studies (32-34) could also be caused by an obstruction of the 
arterial flow before it reaches the cavernosal arteries. This might be caused by radiation dose 
to IPAs. McLaughlin et al. (75) suggested this hypothesis. The IPAs can be visualized by means 
of MR imaging (75,76). The average distance from the CT-defined apex of the prostate to the 
IPAs is 0.9 cm (75). They receive a substantial radiation dose during EBRT (75). During BT the 
IPAs receive radiation as well, although this radiation dose is much lower than during EBRT 
(76).
Merlin et al. (77) conducted an experiment on rats that were irradiated at the pelvic region. 
The levels of endothelin-1, a potential vasoconstrictor (78), were increased in the irradiated 
rats compared to the control group. After induction of an erection by electrostimulation, the 
irradiated rats had significantly lower mean maximal intracavernous pressure. After injection 
of an endothelin-A receptor antagonist there was an improvement in intracavernous pressure 
(77). 
Although there are several studies stressing the role of the IPAs in ED after radiotherapy, 
until now there are no reports analyzing the correlation between radiation dose received by 
the IPAs and ED after radiotherapy.
discussion
There are several important factors in studying ED after radiotherapy. First of all, to accurately 
quantify the negative impact of RT, the patients analyzed should be potent before the com-
mencement of radiotherapy. This must be done preferably by means of a prospective study 
that documents ED by means of a validated questionnaire, filled out by the patient himself. 
Physicians tend to underestimate symptoms causing health related quality of life impairment 
(39). Furthermore the follow-up must be at least 24 months, after which the development 
of ED tends to stabilize (5,10). If follow-up is much longer, other factors than radiotherapy 
might become confounding in analyzing the effect of radiotherapy alone, for example, the 
accumulation or worsening of vascular comorbidities, which themselves will negatively affect 
erectile function outcomes. The Massachusetts Male Aging Study showed that the incidence 
rate of ED in the normal population for men between 60 and 69 years old is 4.6% per year (79). 
Moreover, a large proportion of the patients treated with radiotherapy for prostate cancer also 
receive adjuvant hormonal therapy, which has a large negative impact on sexual functioning, 
also years later (5,11). Therefore, neoadjuvant hormonal therapy and also hormonal therapy, 
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in case of relapse, influence the erectile function status of the patient. Furthermore, since the 
availability of phosphodiesterase 5 inhibitors the use of potency aids must also be taken into 
account when assessing ED. In addition, to find a significant correlation between ED and the 
dose in a certain anatomic structure, a sufficient number of patients is needed.
So far most studies that discuss the dose–effect correlation between radiation-induced 
ED and specific structures are based on a small number of patients (60 or less) (17-20,22,26-
31,60). A small number of patients in combination with the analysis of multiple dose–volume 
histogram parameters in each study may have led to a publication bias. There are only 3 stud-
ies with more than 60 patients (21,57,61).
Roach et al. (21) have reported on the correlation between dose to the penile bulb and ED 
after EBRT. The analysis was performed on 158 patients from a non-randomized dose escala-
tion study for localized prostate cancer who were potent at baseline. Neoadjuvant hormonal 
therapy was used in 24% of the patients. Potency criteria or method of assessment and dura-
tion of follow-up were not reported. Use of potency aids was not accounted for, but most 
patients were treated before the availability of sildenafil. Patients with median penile dose of 
≥ 52.5 Gy had an association with a greater risk of ED after EBRT, compared with those receiv-
ing a dose of <52.5 Gy (p = 0.039).
MacDonald et al. (61) included 226 patients treated with BT in their study. The objective 
was to analyze the dose to the penile bulb in correlation with ED after BT. All patients had an 
erection sufficient for vaginal penetration before therapy and at least 24 months of follow-
up. Assessment of ED was by both patient and physician. Lower ED rates were found in the 
physician-assessed ED. Adjuvant hormonal therapy, number of needles and the planning 
ultrasound target volume were significantly correlated with ED after BT. No significant cor-
relation was found between the dose to the penile bulb and ED after BT. 
Merrick et al. (57) analyzed 128 patients with respect to the correlation between the dose 
to the penile bulb and crura and ED after BT. Data from 2 prospective randomized brachy-
therapy trials were combined. Median follow-up was 29.1 months (range 13.1–42.8). Potency 
was defined as a score of ≥ 13 on the International Index of Erectile Function (IIEF) (54). Pa-
tients treated with hormonal therapy were not excluded. In univariate analysis,amongst 
other factors the penile bulb was significantly correlated to ED after radiotherapy. However, 
in multivariate analysis not the penile bulb but the dose delivered to 50% of the proximal first 
centimeter of the crura was significantly correlated to ED after radiotherapy. This was also the 
case for the pre-implant IIEF score.
This study illustrates that if other anatomic structures are taken into the analysis, they 
may be better correlated than the penile bulb with ED after radiotherapy. In this study that 
anatomic structure is the proximal centimeter of the crura. Though, there are other anatomic 
structures that should be taken into account as well. So far the NVBs have not been analyzed 
with a proper methodology. Furthermore, the radiation dose to the IPAs in correlation with 
ED after radiotherapy has not been analyzed yet, while they receive a substantial radiation 
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dose (75,76), provide arterial flow to corpora cavernosa (16) and arterial flow in the corpora 
cavernosa is decreased in patients with ED after radiotherapy (32-34).
conclusion
Several authors (17-22) advised sparing of the penile bulb to preserve erectile function after 
radiotherapy for prostate cancer. However, the penile bulb seems to play little role in achiev-
ing an erection (62). Two of the three larger studies did not find a significant correlation be-
tween post-radiation ED and the radiation dose to the penile bulb (57,61). We believe that the 
rationale for sparing the penile bulb is not sufficiently supported by the current literature. If 
sparing of the penile bulb is achieved by reducing the margin around the apex, which often 
contains tumor in case of prostate cancer (23-25), an oncological risk is taken, and further-
more, it is uncertain whether this would improve potency-preservation.

Chapter 4
Dose-volume parameters of the corpora 
cavernosa do not correlate with erectile 
dysfunction after external beam 
radiotherapy for prostate cancer:  
results from a dose-escalation trial
Gerard J. van der Wielen
Mischa S. Hoogeman
Gert R. Dohle
Wim L.J. van Putten 
Luca Incrocci
Int J Radiat Oncol Biol Phys 2008;71:795-800
Chapter 4
40
abstract
Purpose 
To analyze the correlation between dose-volume parameters of the corpora cavernosa and 
erectile dysfunction (ED) after external beam radiotherapy (EBRT) for prostate cancer.
Methods and Materials
Between June 1997 and February 2003, a randomized dose–escalation trial comparing 68 Gy 
and 78 Gy was conducted. Patients at our institute were asked to participate in an additional 
part of the trial evaluating sexual function. After exclusion of patients with less than 2 years 
of follow-up, ED at baseline, or treatment with hormonal therapy, 96 patients were eligible. 
The proximal corpora cavernosa (crura), the superiormost 1-cm segment of the crura, and the 
penile bulb were contoured on the planning computed tomography scan and dose–volume 
parameters were calculated.
Results
Two years after EBRT, 35 of the 96 patients had developed ED. No statistically significant 
correlations between ED 2 years after EBRT and dose–volume parameters of the crura, the 
superiormost 1-cm segment of the crura, or the penile bulb were found. The few patients 
using potency aids typically indicated to have ED.
Conclusion
No correlation was found between ED after EBRT for prostate cancer and radiation dose to the 
crura or penile bulb. The present study is the largest study evaluating the correlation between 
ED and radiation dose to the corpora cavernosa after EBRT for prostate cancer. Until there is 
clear evidence that sparing the penile bulb or crura will reduce ED after EBRT, we advise to be 
careful in sparing these structures, especially when this involves reducing treatment margins.
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introduction
Erectile dysfunction (ED) is one of the most common sequelae after radiotherapy for prostate 
cancer, affecting 36–59% of patients after external beam radiotherapy (EBRT) (5,10-12). Find-
ing an anatomic structure responsible for ED after EBRT or brachytherapy would enable physi-
cians to avoid a high radiation dose in these structures and has the potential to reduce ED after 
radiotherapy. The correlation between the radiation dose in specific anatomic structures and 
ED after radiotherapy has been investigated in several studies (17-22,27-31,57,60,61). Most 
reports focused on the penile bulb (17-19,21,22,60,61). However, it should be recognized that 
the penile bulb is not an essential structure in achieving or maintaining an erection (62,63).
The penile bulb is actually the proximal enlargement of the corpus spongiosum. According 
to Dean and Lue (15), the pressure in the corpus spongiosum during erection is only one third 
to one half of the pressure in the corpora cavernosa. Furthermore, several studies demon-
strated a reduced flow in the cavernosal arteries and venous leakage of the corpora cavernosa 
in men with ED after radiotherapy by using Doppler ultrasound (32-34). Therefore the corpora 
cavernosa and not the penile bulb seem to be a likely structure to be responsible for ED after 
radiotherapy.
Only Selek et al. (31) have investigated the correlation between ED after EBRT and the 
radiation dose to the corpora cavernosa. No correlation was found. Unfortunately, this study 
only analyzed 28 patients and several comments were made on its methodology (65). The 
purpose of the present prospective study is to analyze the correlation between ED and dose–
volume parameters of the corpora cavernosa at 2 years after EBRT for prostate cancer with a 
larger number of patients. Furthermore, the comments on the study of Selek et al. (31) are 
taken into account.
Patients and methods
At our center, 404 patients were included in a Dutch multicenter dose–escalation trial (trial 
code CKVO 96-10), in which patients with a localized adenocarcinoma of the prostate were 
randomized to 68 Gy or 78 Gy radiation dose (80,81). The patients in our center were asked to 
participate in an additional part of the trial evaluating quality of life and sexual functioning. 
Of these patients, 268 agreed to participate in the additional part in which sexual function-
ing would be evaluated. Forty-five patients were excluded because of missing baseline data 
on sexual functioning. As there is evidence that (neo)adjuvant hormonal therapy (HT) has a 
significant impact on sexual function and erectile function (5,11,12), 29 patients treated with 
(neo)adjuvant HT were excluded. Another 55 patients already suffered from ED at baseline. 
Furthermore, patients who suffered from a relapse were censored at the time of relapse. A re-
lapse was defined as: biochemical relapse according to the American Society for Therapeutic 
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Radiology and Oncology definition (41), a clinical relapse, or the start of therapy such as HT 
during follow-up or salvage therapy. Ninety-six patients, all potent before radiotherapy and 
with 2 years of follow-up, are the subject of this analysis.
Radiotherapy
The details of this trial have been described before (42). Briefly, four groups were defined 
based on the risk of involvement of the seminal vesicles, according to Partin et al. (43). The 
clinical target volume (CTV) of patients with T1b-T2a tumors with risk of involvement <10% 
consisted of the prostate only. In patients with T1b-T2a tumors with a risk of involvement 
between 10% and 25%, the CTV consisted of prostate plus seminal vesicles until 50 Gy, after 
which the seminal vesicles were excluded from the CTV. For T1b-2a tumors with a risk of in-
volvement of more than 25%, T2b and T3a tumors the seminal vesicles were excluded from 
the CTV after 68 Gy. For T3b and T4 tumors the CTV consisted of the prostate plus seminal 
vesicles. For the first 68 Gy a CTV–planning target volume (PTV) margin of 10 mm was used. 
For the last 10 Gy in the 78 Gy arm a margin of 5mmwas used, except toward the rectum 
where no margin was taken.
In our center, patients were treated at that time with threedimensional conformal radio-
therapy with a three-field technique using one anterior and two lateral wedged fields. The 
prescribed dose was specified in the International Commission on Radiation Units and mea-
surements reference point (2) and was delivered in daily fractions of 2 Gy. Treatment with 
(neo)adjuvant HT, duration, and type of (neo)adjuvant HT was left to the discretion of the 
referring physician. 
Sexual function
The Dutch module on sexual activity (SAc) was used to assess sexual function (44,45). Sexual 
activity was defined as masturbation or intercourse. A skip pattern differentiates sexually ac-
tive vs. inactive men. Sexually inactive men were asked why they were inactive (no desire, no 
partner, partner had no desire, ED, or other reasons). Sexually active men were asked whether 
they had experienced problems with achieving or maintaining erections. The definition of ED 
was (almost) always having problems in achieving or maintaining an erection, or not being 
sexually active because of erectile problems. The patients had to answer the SAc question-
naire at baseline and at 6 months, 1, 2, and 3 years after the start of EBRT.
Because the study was designed before the introduction of oral phosphodiesterase-5 
(PDE5) inhibitors, no assessment of potency aids was done during the study protocol. Hence 
a questionnaire was developed to retrospectively assess the use of potency aids: PDE5-inhib-
itors, intracavernosal injections, intraurethral alprostadil, vacuum device, or a penile ring. The 
questionnaire contained the following items: the use of potency aids on a regular base before 
EBRT, during the first 2 years after EBRT, or after more than 2 years after EBRT. Patients could 
answer ‘‘yes’’ or ‘‘no.’’ When answering yes, they were asked to make a choice between different 
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kinds of potency aids. This questionnaire was sent in June 2006 to all pretreatment potent 
patients with at least 2 years of follow-up and who were alive at the moment the question-
naire was sent.
Contouring
The proximal penis was contoured on the planning CT scan by one single observer (G.J.W.) 
blinded for the potency status of the patient. Contouring of the penile bulb was based on a 
report of Wallner et al. (64). The penile bulb was contoured until both corpora cavernosa do 
not join together anymore in the inferior axial slices. Contouring of the crura was continued in 
the inferior slices. Figure 1 shows a planning CT scan with contouring of the penile bulb and 
crura. Mulhall et al. (63) reported that the superiormost 1-cm segment receives the highest 
radiation dose after which there is a steep dose decline. Therefore the superiormost 1-cm 
segment of the crura was subtracted as a separate structure next to the structure of the whole 
crura and penile bulb.
Figure 1. Contoured structures on a planning computed tomography (CT) scan: penile bulb (white) with the crura left and right (black). The 
penile bulb was contoured (left) until the corpora cavernosa do not join together anymore in the inferior CT slices (right).
Statistics
The following dose–volume variables were analyzed for the crura, the superiormost 1-cm 
segment of the crura and penile bulb: mean dose, maximum dose, volume, relative volume 
receiving 5–80 Gy in intervals of 5 Gy (rV5, 10, 15–80), and absolute volume receiving 5–80 
Gy in intervals of 5 Gy (aV5, 10, 15–80). Differences between patients with and without ED 
were tested with the Kruskal-Wallis and the Pearson chi-square test. Statistical analysis was 
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performed with SPSS, version 14.0, software. Level of statistical significance was adjusted for 
multiple parameters and set at p < 0.01.
results
The use of potency aids was retrospectively assessed using a mailed questionnaire. Fifteen 
patients were deceased and the addresses of three patients could not be retrieved. Therefore 
the questionnaires were sent to 78 patients, of whom 70 patients responded (90%). Of these 
70 patients, only 1 patient used a potency aid before the start of EBRT and continued using 
intracavernosal injections after EBRT. Six patients started using oral PDE5 inhibitors within 2 
years after EBRT. All of these 7 patients, except 1, also indicated to suffer from ED in the SAc 2 
years after EBRT.
At 2 years after EBRT, 35 of the 96 patients (36%) suffered from ED. There were no statisti-
cal significant differences in patient characteristics between the patients with and without 
ED 2 years after EBRT (Table 1). No significant differences were found between mean dose, 
maximum dose, and volume of the different structures between patients with and without ED 
2 years after EBRT (Table 2). Figure 2 shows the absolute dose–volume histogram (DVH) com-
paring the average DVHs for the different structures of patients with and without ED 2 years 
after EBRT. Figure 3 shows the relative DVH comparing the average DVHs for the different 
structures of patients with and without ED 2 years after EBRT. No statistically significant cor-
relations were found between the different dose–volume variables and ED 2 years after EBRT.
Parameter ED (n=35) No ED (n=61) p value
Treatment arm 78 Gy 19 / 35 33 / 61 0.99
Mean age, years 69 68 0.83
Mean PSA, μg/L 12.8 11.2 0.42
T-stage ≥ T3 8/34 20/60 0.32
Gleasonscore ≥ 7 15/30 28/52 0.74
Diabetes Mellitus 2/35 1/61 0.27
Cardiovascular history
Treatment arm 78 Gy
10/35
19 / 35
16/61
33 / 61
0.80
0.99
Table 1. Patient characteristics. 
ED = erectile dysfunction
PSA = prostate specific antigen
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Parameter
ED (n=35)
mean (± SD)
No ED (n=61)
mean (± SD) p value
Crura mean dose
Crura max dose
Crura volume
Crura 1cm mean dose
Crura 1cm max dose
Crura 1cm volume
Penile bulb mean dose
Penile bulb max dose
Penile bulb volume
40.6 ± 17.9
67.7 ± 11.7
7.9 ± 2.3
52.6 ± 17.8
67.7 ± 11.7
4.0 ± 1.0
53.4 ± 16.8
70.1 ± 9.2
4.6 ± 1.5
39.9 ± 13.8
69.6 ± 5.9
8.5 ± 2.6
54.2 ± 13.4
69.6 ± 5.9
4.1 ± 1.1
53.3 ± 13.1
71.3 ± 5.4
5.1 ± 1.8
0.78
0.78
0.16
0.90
0.80
0.50
0.71
0.87
0.12
Table 2. Mean dose in Gy, maximum (max) dose in Gy and volume in mL of the crura, the superiormost 1-cm segment of the crura (Crura 1cm) 
and the penile bulb for patients with and without erectile dysfunction (ED) at 2 years after external beam radiotherapy.
discussion
Prostate cancer is the most common type of cancer for men in Western countries with the 
exception of skin cancer (82). A common treatment for prostate cancer is radiotherapy. Unfor-
tunately, this leads to ED in 36–59% of the patients (5,10-12). Hence a large patient popula-
tion would benefit from finding a new technique to reduce ED after radiotherapy for prostate 
cancer.
Radiation dose to the neurovascular bundles could be responsible for ED after radiothera-
py. So far, only brachytherapy studies analyzed this possibility (26-30). None of these studies 
could find any statistically significant correlation between radiation dose to the neurovascular 
bundles and ED after brachytherapy for prostate cancer.
Many reports (17-19,21,22,60,61) that try to find a correlation between the radiation dose 
in a specific anatomic structure and ED after radiotherapy for prostate cancer focused on the 
penile bulb, but results are contradictory (17-22,27,30,31,57,60,61). Two of the three larger 
studies, with more than 60 patients, did not find a statistically significant correlation between 
the radiation dose to the penile bulb and ED after radiotherapy. In the present study, we were 
not able to find this correlation either.
Selek et al. (31) were the only ones who analyzed the correlation between ED and the ra-
diation dose to the corpora cavernosa after EBRT for prostate cancer. They did not find any 
positive correlation. However, Buyyounouski et al. (65) argued that this correlation was not 
found for two reasons. First, the small number of patients might be the reason why no statisti-
cally significant correlation was found. Second, only the first centimeters of the crura receive 
a substantial radiation dose (63). Selek et al. (31) contoured the corpora cavernosa and penile 
bulb until the inferiormost aspect of the ischial tuberosities. As a consequence, the volumes 
of the analyzed structures were much larger than previously described. This shifts the DVH to 
lower doses for any given volume, making the differences between patients with and without 
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ED smaller. Statistical significance would be increasingly more difficult to achieve. However, 
this argument is only valid for the relative dose–volume parameters and has no influence on 
absolute dose–volume parameters in the higher dose region.
In the present article, we took the comments from Buyyounouski et al. (65) into account. 
To analyze the corpora cavernosa, only the crura were analyzed, including a separate analy-
sis of the superiormost 1-cm segment of the crura. Mulhall et al. (63) demonstrated that the 
superiormost 1-cm segment of the crura comprehends the high radiation dose area, whereas 
there is a steep decline in radiation dose inferior of this segment. Nevertheless, even with a 
group of 96 patients, the present report still did not find any statistically significant correlation 
between ED and the radiation dose to the crura after EBRT for prostate cancer.
Next to the comments from Buyyounouski et al. (65), this study also took potency aids 
into account. The use of potency aids before the start of EBRT was low. Most patients using 
potency aids also indicated to suffer from ED in the SAc; therefore, the use of potency aids was 
not a large confounding factor in this study.
There was no validated Dutch questionnaire available to assess sexual function at the time 
of study design. However, there was experience with the SAc in several studies (45,52,53) and 
it has been evaluated by Korfage et al. (44). The SAc does have some advantages over the 
commonly used International Index of Erectile Function (54). A large part of this index is based 
on the assumption that patients have sexual intercourse with penetration. Therefore it is not 
suitable for homosexual men and patient without a (sexually active) partner.
Three studies have previously analyzed the correlation between ED and the radiation dose 
to the corpora cavernosa after brachytherapy for prostate cancer (20,30,57). One of these 
studies (57) (with the largest number of patients, n = 128) found a significant correlation, 
whereas the other two did not find a statistically significant correlation between the radiation 
dose to the corpora cavernosa and ED after brachytherapy for prostate cancer (20,30). There 
is a possibility that the present study still lacks statistical power. Another possibility might be 
that ED after brachytherapy has another etiology than ED after EBRT caused by the difference 
in dose distribution, but this does not seem logical.
It is certainly possible that the reduced flow in the cavernosal arteries demonstrated by 
several studies in men with ED after radiotherapy (32-34) is caused by radiation damage to the 
internal pudendal arteries and accessory pudendal arteries that supply the cavernosal arteries 
instead of the cavernosal arteries themselves. The internal pudendal arteries also receive sub-
stantial radiation dose (75,76), but so far there is no report analyzing the correlation between 
the radiation dose to the internal pudendal arteries and ED after radiotherapy. This correlation 
should certainly be analyzed in future studies.
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conclusion
Although it was suggested in previous publications (62,63) that the radiation dose to the 
corpora cavernosa might be correlated to ED after EBRT for prostate cancer, no evidence for 
this correlation was found in the present study as in the previous study. Unfortunately, there 
is no clear evidence yet that avoiding high radiation dose in a specific structure will decrease 
ED after EBRT (83). Therefore we believe that so far no adjustments should be made in the 
treatment plans to avoid high radiation dose in a specific structure - especially if sparing of 
such a structure involves reducing treatment margins, an oncologic risk is taken, whereas it is 
uncertain whether this will improve potency preservation.
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abstract
Introduction
External beam radiotherapy for prostate cancer leads to erectile dysfunction in 36%-43% of 
patients. The underlying mechanism is largely unknown, although some clinical studies sug-
gest that the arterial supply to the corpora cavernosa is responsible. Two animal experimental 
studies reported on the effects of a single fraction of prostate irradiation on the penile struc-
tures. However, irradiation in multiple fractions is more representative of the actual clinical 
treatment.
Aim
The present prospective, controlled study was initiated to investigate the effect of fraction-
ated prostate irradiation on the arteries of the corpora cavernosa.
Main Outcome Measures
Histological evaluation of the penile tissue in comparision with control rats at 2, 4 and 9 weeks 
after irradiation.
Methods
The prostate of twelve rats was treated with external beam radiation in 5 daily fractions of 
7.4 gray. Three control rats were treated with sham irradiation. Prostatic and penile tissue was 
evaluated for general histology (hematoxylin-eosin). The penile tissue was further evaluated 
after combined staining for collagen (resorcin fuchsin) and α-smooth muscle actin (SMA) 
(Biogenex).
Results
The prostate showed adequate irradiation with fibrosis occuring at 9 weeks after irradiation. 
The corpora cavernosa showed arteries that had developed loss of smooth muscle cells ex-
pressing SMA, thickening of the intima and occlusions. All the control rats maintained normal 
anatomy.
Conclusion
This is the first animal experimental study that demonstrates changes in the arteries of the 
corpora cavernosa after fractionated irradiation to the prostatic area. The preliminary data 
suggests that erectile dysfunction after radiotherapy might be caused by radiation damage 
to the arterial supply of the corpora cavernosa.
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introduction
Prostate cancer is the most common type of cancer for men in Western countries with the ex-
ception of skin cancer (82). Both localized and locally advanced prostate cancer can be treated 
with external beam radiotherapy. However, 36% to 43% of the patients develop permanent 
erectile dysfunction during the first few years after external beam radiotherapy for prostate 
cancer (5,12). 
Reducing erectile dysfunction after radiotherapy would help a large number of prostate 
cancer patients remain sexually active and improve their quality of life (37). Radiation treat-
ment plans can be adapted to minimize the radiation dose to a specific anatomical structure, 
for instance by choosing specific angles for the radiation beams, as is usually done for the 
rectum. If the mechanism of erectile dysfunction after radiotherapy is fully understood, then 
it is possible to minimize the radiation dose to the anatomical structures that are involved.
Three anatomical structures are essential for an adequate penile erection: the neurovascu-
lar bundles / cavernous nerves supply the penis with nitric oxide to initiate an erection, after 
which the arterial inflow through the internal pudendal and cavernosal arteries increases and 
the corpora cavernosa build up pressure by adequate trapping of blood (the veno-occlusive 
mechanism) to achieve and maintain an erection (15). Although clinical studies investigated 
several anatomical structures, the cause of erectile dysfunction after radiotherapy is still 
largely unknown (83,84). There is some clinical evidence that damage to the arterial supply of 
the corpora cavernosa might be responsible (32-34,57). 
Because clinical studies have not been able to elucidate the cause, animal experimental 
studies would seem to be a better model. Two rat studies reported defects in the vascular 
supply and loss of nerve and smooth muscle fibers. (74,77). However, these studies were per-
formed with a single fraction of radiation, while clinical radiotherapy for prostate cancer is 
delivered in multiple fractions. Therefore the present study has been initiated to investigate 
the arteries in corpora cavernosa of the rat after fractionated irradiation of the prostatic area.
materials and methods
Fifteen male Sprague-Dawley rats (Harlan, Zeist, The Netherlands), 2-3 months of age, were 
randomized into three groups of five rats. Rats were housed according to institutional guide-
lines, and procedures were carried out in compliance with the standards for the use of labora-
tory animals. For each group, 4 rats received external beam radiation and 1 rat was used as 
a control. All control rats were sham irradiated. The rats were anaesthetized with isoflurane/
N2O/O2 and immobilized in a supine position for approximately 7 minutes per radiation frac-
tion. A lead shield (3 mm thick) was used to protect the testes and bowel, while an opening, 
measuring 30 mm wide and 40 mm long, allowed irradiation of the prostatic area (Figure 
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1). The lower border of the field was positioned 5 mm under the cartilage of the penis. The 
lateral borders were chosen 15 mm left and right of the median. The rats were irradiated with 
an anterior-posterior radiation field and a total dose of 37 gray, which was delivered during 
5 daily fractions of 7.4 gray. This fractionation scheme is an equivalent of 19 fractions of 3.4 
Gy, which is currently investigated in our institute. Moreover, Van den Aardweg et al. reported 
that five fractions of 7.6 Gy to the rectum caused no major toxicity.14 Radiation was delivered 
with a Philips RT250 Orthovolt X-ray machine (Philips, Eindhoven, The Netherlands) operating 
at 200 kV with a source-to-skin distance of 30 cm, a 4 x 6 cm2 field and a dose rate of 1.50 Gy/
min. 
At 2, 4 and 9 weeks after irradiation a group of rats was sacrificed. This study was approved 
by the Dutch Animal Experiment Committee.
Ventral Prostate Lobe
Seminal Vesicles
Coagulating Gland
Bladder
Dorsolateral Prostate Lobe
Urethra
Rectum
Corpora Cavernosa
Penile Bulb
Radiation Field
Figure 1 is a schematic picture of the anatomy of the prostate, rectum, bladder and penis of the rat and the radiation field.
Histology
The prostate and the penis were removed, fixed in 10 % formalin for a maximum of 48 hours 
and embedded in paraffin. Sections were cut at 4 μm thick and attached to silane-coated 
slides. General histology staining was performed with hematoxylin-eosin (HE). The slides 
were then stained with both resorchin fuchsin to identify the collagen and elastin of the in-
tima, and immunohistochemistry to identify the α -smooth muscle actin in smooth muscle 
cells. Immunohistochemical staining was performed with an antibody to α-smooth muscle 
actin (clone 1A4, 1:100, Biogenex, San Ramon, Ca, USA). The Envision HRP System (DAKO, 
Glostrup, Denmark) was used for visualization of the expression of antibodies. Pre-treatment 
Changes in the Penile Arteries after Irradiation
53
was performed with 0.1% protease from streptomyces griseus in phosphate buffered saline 
(SIGMA-ALDRICH, Zwijndrecht, Netherlands) at 37º Celsius for 10 minutes. 
Two observers (GJW and MV) analyzed the slides blinded to whether the slides were con-
trol rats or irradiated rats.
results
Radiation-induced changes in the prostate 
Histological samples of the rat prostate showed adequate irradiation damage (Figure 2). Two 
weeks after irradiation the prostate showed edema and atrophy in parts of the epithelium. 
Four weeks after irradiation the tissue recovered from the edema, but there was progression of 
the atrophic area of epithelium, fibrosis and the presence of macrophages and lymphocytes. 
Two rats died at 8 weeks after irradiation. These two rats were not analyzed in this study. 
The remaining irradiated rats had to be sacrificed at 9 weeks, because they developed rectal 
bleeding in combination with loss of weight. Histological evaluation showed a swollen rec-
tum, known as a megacolon. Furthermore, the rectal arteries showed extensive thickening 
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Figure 2 shows histology of prostatic and penile tissue of a control rat and rats sacrificed at 2, 4 and 9 weeks after irradiation. 
The first row (prostate) shows the prostate stained with hematoxylin-eosin. Two weeks after irradiation edema is observed, followed by 
inflammation at 4 weeks and fibrosis at 9 weeks after irradiation.
The second row (dorsal penile artery) shows the dorsal penile artery with resorcin fuchsin and α-smooth muscle actin staining. The histology after 
irradiation shows smooth muscle cells in apoptosis (examples indicated with an arrow) and an increase in collagen in the arterial wall. At 9 weeks 
an artery is shown with severe thickening of the intima and loss of most smooth muscle cells expressing α-smooth muscle actin.
The third row (corpus cavernosum) shows arteries in the corpora cavernosa with resorcin fuchsin and α-smooth muscle actin staining. Again there 
is a decrease in smooth muscle expressing α-smooth muscle actin. The tissue sample at 4 weeks after irradiation shows an occlusion of an artery 
caused by a thrombus.
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of the intima. The prostate tissue of these rats showed progression of the atrophic area of 
epithelium and fibrosis, while there was a clear reduction in the presence of macrophages 
and lymphocytes. 
All control rats maintained normal anatomy.
Radiation-induced changes in the arteries of the penis
The proximal penis, which was on the edge of the radiation field in the scatter dose area, 
showed vascular changes in all irradiated rats (Figure 2). Arteries in the proximal penis showed 
apoptotic cells, as indicated by morphological signs, in the smooth muscle layer of the arterial 
wall 2 weeks after irradiation. An increase in collagen content in arterial walls and the first 
arterial occlusions by thrombosis were visible after 4 weeks. Nine weeks after irradiation there 
was a further increase in collagen content and a further loss of smooth muscle cells expressing 
α-smooth muscle actin. Furthermore, arteries were visible with extensive thickening of intima.
The distal penis, which did not receive radiation, did not show any histological changes 
(data not shown). The control rats also maintained normal anatomy.
discussion
The side-effects of radiotherapy can be reduced by adapting the treatment plan in such a 
manner that the responsible anatomical structure is spared during irradiation. However, clini-
cal studies have not led to a clear understanding which structure should be spared to reduce 
the risk of erectile dysfunction after radiotherapy for prostate cancer. Therefore, there is an 
important role for animal experimental studies to find the mechanism that causes this form 
of erectile dysfunction. 
To our knowledge, this is the first study demonstrating that fractionated external beam 
radiotherapy to the prostatic area of the rat induced changes in the penile arteries. Arter-
ies in the proximal penis showed a reduction of smooth muscle cells expressing α-smooth 
muscle actin and an increase in collagen content in the arterial wall. Furthermore, arteries that 
showed thickening of the intima and occlusions were visible.
Our findings are supported by the two other studies, although these studies used a single 
fraction of irradiation. Merlin et al. performed an experiment in which rats were treated with a 
single fraction of 10 or 20 Gy to the prostatic area (77). Endothelin-1 (a potential vasoconstric-
tor (78)) was increased in rats treated with 20 Gy. Merlin et al. suggested that an increased 
endothelin 1 level could be involved in development of atherosclerotic lesions (77). 
Carrier et al. conducted an experiment in which rats were treated at the prostatic area with 
a single fraction 10 or 20 Gy and found a decrease in nitric oxide synthase (NOS)-containing 
nerve fibers in the proximal shaft of the penis (74). Furthermore, they concluded that there 
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were defects in the vascular supply of the erectile tissue and a decrease in cavernous smooth 
muscle.
In the present study a radiation protocol with fractionated radiotherapy was chosen, be-
cause this is more representative of the actual clinical treatment. However, it is difficult to 
conclude if this leads to different effects by a comparison with these two studies, because 
their focus, endothelin-1 and NOS containing nerve fibers, has been different.
Three clinical studies reported a reduced flow in the cavernosal arteries, which are supplied 
by the internal pudendal arteries, in patients with erectile dysfunction after radiotherapy (32-
34). The average distance from the computed tomography (CT)-defined apex of the prostate 
to the internal pudendal arteries is 0.9 cm (75). This means that the internal pudendal arter-
ies will often be within the commonly used 1 cm margin where the full treatment dose is 
delivered. Although the arteries toward the corpora cavernosa were not investigated in our 
study, the rats developed changes in the arterial wall in the rectal arteries that received the 
full treatment dose and in the proximal penis itself. This is in agreement with the study of 
Goldstein et al. in which two patients with erectile dysfunction after radiotherapy showed 
bilateral narrowing of the internal iliac arteries and occlusions of the internal pudendal and 
penile arteries on selective pudendal arteriography (32). In future studies the arteries supply-
ing the corpora cavernosa of the rat will need to be studied in detail. 
However, one should not exclude the possibility that the changes in the arteries might be 
influenced by radiation damage to the neurovascular bundles. The animal cavernous nerve 
injury model, including intracavernosal pressure measurements, has been used in various 
studies to investigate methods to reduce erectile dysfunction after radical prostatectomy 
(85-88). Some of these studies reported a decrease in smooth muscle as well as an increase in 
fibrosis in the corpora cavernosa (89). Furthermore, androgen deprivation can induce similar 
changes (90).
Van den Aardweg et al. reported that no rats developed a megacolon after being treated 
with five daily fractions of 7.6 Gy to the rectum (91). This is in contrast with our findings that 
showed development of a megacolon in four rats. A likely explanation is that they used an 
opening in their lead shielding which is half the size of our opening (20mm x 15mm). An-
other experiment was performed with five fractions of 4.8 Gy and a 3 mm lead shielding with 
an opening of 20 mm long and 15 mm wide (unpublished data). However, the histological 
changes were very small compared to the control rats.
This pilot study, by its nature, included a limited number of rats. Future experiments, in-
cluding intracavernosal pressure measurements, with a larger number of rats are needed to 
quantify and statistically confirm the preliminary data of this study. For future experiments, 
we advise to use a 3 mm lead shielding with a 20 mm x 15 mm wide opening and five daily 
fractions of more than 4.8 Gy and up to 7.4 Gy.
At present we are conducting a clinical study in which the internal pudendal arteries are 
imaged with magnetic resonance imaging with contrast in patients who will be treated with 
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external beam radiotherapy for prostate cancer. The correlation between the radiation dose 
received by the internal pudendal arteries and erectile dysfunction after radiotherapy can 
then be analyzed. On the other hand, new techniques are being developed to safely reduce 
the radiation dose to all structures surrounding the prostate, including those essential to a 
penile erection (92). Until the mechanism of erectile dysfunction after radiotherapy is fully 
understood, the sparing of all tissues surrounding the prostate, including those structures 
essential to a penile erection, is the most feasible way to reduce the risk of erectile dysfunction 
after radiotherapy for prostate cancer.
conclusion
This is the first animal experimental study demonstrating changes in the arteries of the rat 
penis after fractionated irradiation of the prostatic area. Arteries developed loss of smooth 
muscle, intimal thickening and occlusions after five daily fractions of 7.4 Gy. The preliminary 
data suggest that erectile dysfunction after radiotherapy might be caused by radiation dam-
age to the arterial supply of the corpora cavernosa. Further experimental studies are needed 
to support these preliminary data. 
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abstract
Purpose 
A fully automated, fast, on-line prostate repositioning scheme using implanted markers, 
kilovoltage/megavoltage imaging, and remote couch movements has been developed and 
clinically applied. The initial clinical results of this stereographic targeting (SGT) method, as 
well as phantom evaluations, are presented.
Methods and Materials
Using the SGT method, portal megavoltage images are acquired with the first two to six moni-
tor units of a treatment beam, immediately followed by acquisition of an orthogonal kilovolt-
age image without gantry motion. The image pair is automatically analyzed to obtain the 
marker positions and three-dimensional prostate displacement and rotation. Remote control 
couch shifts are applied to correct for the displacement. The SGT performance was measured 
using both phantom images and images from 10 prostate cancer patients treated using SGT.
Results
With phantom measurements, the accuracy of SGT was 0.5, 0.2, and 0.3mm (standard de-
viation [SD]) for the left–right, craniocaudal, and anteroposterior directions, respectively, 
for translations and 0.5° (SD) for the rotations around all axes. Clinically, the success rate for 
automatic marker detection was 99.5%, and the accuracy was 0.3, 0.5 and 0.8 mm (SD) in the 
left–right, craniocaudal, and anteroposterior axes. The SDs of the systematic center-of-mass 
positioning errors (Σ) were reduced from 4.0 mm to <0.5 mm for all axes. The corresponding 
SD of the random (σ) errors was reduced from 3.0 to <0.8 mm. These small residual errors were 
achieved with a treatment time extension of <1 min.
Conclusion
Stereographic targeting yields systematic and random prostate positioning errors of <1 mm 
with <1 min of added treatment time.
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introduction
Recent advances in electronic portal imaging devices (EPIDs) (93,94), as well as linear acceler-
ator-integrated kilovoltage (kV) scanners (95,96), have enabled detailed investigation of the 
uncertainties in target position during external beam radiotherapy (EBRT). These uncertain-
ties, stemming from deviations in patient anatomy during treatment relative to the anatomy 
during planning, lead to inaccuracies in the delivered dose distribution and possible loss of 
tumor control with an increased risk of complications. To account for the uncertainties, plan-
ning margins are added to the clinical target volume (CTV) to obtain the planning target vol-
ume (PTV) (2), while ensuring adequate CTV dose coverage. One of the goals of image-guided 
RT is to allow for the reduction of these margins through the reduction of the geometric errors 
during treatment, thereby potentially reducing toxicity.
Combined with kV and/or megavoltage (MV) daily imaging (on-line approach), implanted 
markers not only allow for elimination of large geographic misses, but also for the reduc-
tion of both random and systematic errors(97). Studies of the effect of systematic geometric 
misses due to a nonrepresentative rectal shape during acquisition of the planning computed 
tomography (CT) scan have indicated that such misses result in increased biochemical and 
clinical failure, even when margins of 1 cm have been applied (98,99). On-line corrections can 
eliminate such misses while simultaneously allowing for smaller CTV–PTV margins (100-103).
This report describes stereographic targeting (SGT), a method for fast and accurate on-line 
prostate positioning with implanted markers using orthogonal cross-fire kV/MV imaging. The 
clinical data obtained for the first 10 patients treated with SGT are presented.
methods and materials
Preparation
Before CT scanning, cylindrical gold markers (1 mm x 5 mm; Heraeus GmbH, Engineered 
Materials Division, Hessen, Germany) were implanted in the prostate transperineally using 
18-gauge needles under transrectal ultrasound guidance. Two markers were placed near the 
base and two near the apex. At least 1 week after implantation, the patients were scheduled 
for the planning CT scan (Somatom Sensation Open, Siemens Medical Solutions, Erlangen, 
Germany) with a reconstruction slice thickness of 2.5 mm. The interval between implantation 
and planning allowed for any edema to resolve so that the anatomy in the scan would be 
representative for treatment (101,104). The reference positions of the markers with respect to 
the isocenter were reconstructed with a tool (Define Marker 3D) in the EPID software program, 
which in the present study used digitally reconstructed radiographs (DRRs). The input for this 
tool was at least two DRRs with sufficient beam angle separation (minimally 60˚). The marker 
positions were first manually identified in at least two DRRs by clicking on the two edges of 
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the marker. A rectangular contour was automatically drawn around the marker according to 
the two clicked points. Next, the tool automatically reconstructed the three-dimensional (3D) 
marker positions from the identified two-dimensional positions. For each marker identified 
on a DRR, the expected marker position in the other DRRs was indicated automatically to 
facilitate the process. The obtained reconstructed 3D marker reference positions were stored 
for later use in SGT. 
Equipment
The cross-fire kV/MV imaging system (Fig. 1) used in SGT was developed on the Synergy linear 
accelerator (Elekta, Crawley UK). For MV imaging, either a charge-coupled device, camera-
based EPID (TheraView NT [TNT], Cablon Medical, Leusden, The Netherlands) or an iView GT 
flat-panel EPID (Elekta, Crawley, UK) can be used. In the present study, the TNT EPID (Cablon 
Medical) was used. The gantry-mounted XVI system enables acquisition of a planar image 
from the kV beam orthogonal to the MV beam directly before MV acquisition. Hence, the XVI/
EPID combination can be used for acquisition of an orthogonal pair of images without inter-
mediate gantry rotation. The TNT software was extended to provide all necessary tools for 
image processing, marker detection, analysis, and application of the positioning corrections.
The Theraview Couch Set-up Assistant (TCSA) system applies patient positioning correc-
tions by remotely steering the Elekta Precision couch. The prototype of the TCSA used in this 
study was developed in collaboration with Cablon Medical and Elekta. It consisted of an inde-
pendent controller personal computer connected to the couch control cabinet and to the TNT 
workstation. Treatment plan information, as well as positioning corrections, were transferred 
from TNT software to the TCSA controller while safety checks were being performed. The 
checks included correspondence of the patient and treatment plan identification numbers 
with the record and verify system, TCSA and couch hardware status, and communication 
integrity. In the case of any inconsistency, the TCSA moves to a passive state and stops any 
motion being executed. In the ‘‘off-line mode,’’ the relative couch position as read by the TCSA 
is first zeroed by pressing a dedicated button on the couch’s manual controls. Any pretreat-
ment corrections such as those generated by an off-line correction protocol are automatically 
executed by the TCSA while the motion enable bar is pressed. In the ‘‘on-line mode’’ used in 
SGT, zeroing the couch readout and execution of pretreatment corrections are the same but 
shifts of a maximum of 2 cm are also allowed under remote control of the TNT software. In the 
on-line mode, the radiographer in the control room must hold the keyboard spacebar of the 
TNT workstation to allow this couch motion.
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Figure 1. Coordinate system: anteroposterior (Z), craniocaudal (Y) and left–right (X), with orthogonal imagers and sample clinical images. (Top 
left) Megavoltage image. (Top right) Kilovoltage image.
SGT execution
At the start of each treatment fraction, the patient was positioned according to the alignment 
of the room lasers with the skin marks. If available, pretreatment (‘‘off-line’’) corrections were 
executed by the TCSA. Next, a lateral planar kV image (kVI) of 1024 x 1024 pixels was acquired 
with the XVI system using a dedicated collimator that projects a field size of 10 x 10 cm2 at the 
isocenter. The clinical kVI acquisition settings (eight frames, 40 ms, 32 mA) resulted in a maxi-
mal skin dose of approximately 1.5 mGy. The acquired kVI was then automatically imported 
into the TNT workstation. The kVI acquisition was immediately followed by MV image (MVI) 
acquisition with the first part (2–6 monitor units [MU]) of the anteroposterior treatment beam. 
For IMRT, we apply the split IMRT field technique (105). In the split IMRT field technique, the 
IMRT field is divided into a static and a modulated field, and an MVI of the former field is used 
in SGT. Congruence of the isocenter positions of the two orthogonal imagers was checked 
daily as a part of our routine quality assurance program and was within 0.5 mm during the 
study period.
On the basis of the automatically extracted two-dimensional positions of the markers in 
the two orthogonal images, the 3D marker positions were reconstructed in the treatment 
coordinate system. The difference between the center of mass (COM) of the markers during 
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a treatment fraction and the corresponding COM from the planning CT is the translational 
correction. Prostate rotations about the COM with respect to the planning CT scan for all three 
axes were also calculated. The translational correction was remotely executed under TCSA 
guidance if the magnitude of the correction vector was >2 mm. After the correction has been 
applied, the SGT loop can be re-entered to acquire and analyze images for verification Fig. 
2). If no further correction or verification is necessary, all treatment beams are delivered. In 
the present study, 3D verification using on a second kVI/MVI pair was always performed. In 
subsequent sections, we describe the procedure to automatically obtain the marker positions 
from the image pair in more detail.
Patient setup
kV/MV acquisition
Find displacements
Treat
Verify ?
Y
N
Time ranges
EPID/XVI: 10-15s
Execute corrections
Matching: 2-3s
Inspection: 10-15s
Automatic couch
corrections: 0-12s
Figure 2. Stereographic targeting workflow with observed time ranges for various subprocesses.
Automatic marker detection and 3D position reconstruction
For the MVI, the image coordinate system was determined by registration of the detected field 
edge with the planned field edge (106). For the kVI, the image coordinate system was retrieved 
from the XVI database. For both images, fixed pattern noise was eliminated by dividing each 
image with a flat field image. Automatic marker detection in each image required a set of 
previously obtained reference marker positions for the corresponding view, as described in 
the section ‘‘Preparation’’. The applied algorithm for automatic marker detection was based on 
a combination of template matching and marker extraction kernels (MEKs) (107), adapted for 
the rotations of individual markers. For each projected marker, the MEKs were calculated for a 
set of predetermined in-plane marker rotations. The range of these rotations was determined 
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by the initial marker orientation plus a maximal MEK rotation value (θ), which is set as an 
option in TNT. A θ value of 20˚ was sufficient for marker detection in the present study. The 
sum of the rotated MEKs formed the effective MEK, which was then convolved with the input 
image to form the marker response image (Fig. 3b,f ). The image was binarized with adap-
tive thresholding to select only those features with sufficient marker response. Although the 
markers stand out in the binary image, some features with shapes similar to markers (e.g., 
because of bony edges, calcifications, or image noise) are also visible (Fig. 3c,g). To obtain the 
true marker positions from the spots in the binary image, Chamfer matching (108) was used. 
Because the Chamfer match was performed with all markers simultaneously, it was insensi-
tive to the features in the binary image that did not represent the markers. After Chamfer 
matching, the centroid of the spot with greatest response in the neighborhood of a marker 
was chosen as the detected marker position. With the marker positions thus identified in two 
orthogonal images, the 3D rigid body transformation that best mapped the marker reference 
positions onto the positions during a treatment fraction was found analytically from the 
leastsquares minimization (109). The residue errors per marker directly yielded information 
about the rigidity of the template, as well as whether the markers were associated with the 
correct blobs. The quality of the match, both overall and for individual markers, could thus 
be assessed. In the visualization of the match results, the markers were presented with color 
coding to indicate this quality.
e
a b c d
hgf
Figure 3. Marker matching on (a–d) megavoltage image and (e–h) kilovoltage image. Reference marker positions indicated by solid white 
rectangles and detected marker positions by dotted white rectangles. (a,e) Initial images, (b,f) images after convolution with marker extraction 
kernel, (c,g) images after binarization of convolution images, and (d,h) final images with detected marker positions.
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Phantom measurements
The accuracy and success rate of SGT marker matching was studied for the clinically applied 
(kV/MV) image combination, as well as for another approach using two MVIs. Furthermore, 
the performance of SGT marker matching as a function of MV beam energy, as well as MV 
exposure, was investigated.
A phantom consisting of a stack of 10 square (41 x 41 cm2) plates of RW3 (PTW, Germany) 
water-equivalent material was used. Each plate had a thickness of 1–2 cm so that the com-
bined dimension of the phantom was 41 x 41 x 20 cm3. Six gold markers were embedded in 
grooves on the two opposite faces of the central plate, with three markers on each face. The 
markers were placed such that the intermarker separation was 2, 4, and 1 cm in the left–right, 
craniocaudal, and anteroposterior directions, respectively. The phantom was placed on the 
treatment couch and shifts ranging from 0 to 20 mm in each direction with step sizes of 5 
mm were executed using couch motion. Two orthogonal MVIs (MV ‘‘anteroposterior’’ and MV 
‘‘lateral’’) were acquired with varying exposures (1, 2, 4, 8 and 32 MU) after each shift, using the 
three available beam energies (6, 10, and 18 MV). A lateral kVI (kV ‘‘lateral’’) was also acquired 
after each MVI acquisition at the clinically applied exposure for each phantom position.
The marker matching accuracy and success rate in the presence of combined phantom 
rotations and translations were also studied using a dedicated phantom consisting of a water-
filled box (30 x 20x 30 cm3) made of polymethyl metacrylate. Four gold markers were embed-
ded in grooves on the two faces of a polymethyl metacrylate slab (30 x 20 x 2 cm3), with two 
markers on each face. This slab was immersed in the water-filled box. Predefined rotations 
about the three principal directions (range, 0–20˚; with a step size of 5˚) were applied to the 
phantom with markers. Both kVI/MVI and MVI/MVI orthogonal images were acquired after 
each rotation step. Phantom translations were applied using couch shifts, and MVI exposures 
of 6 MU and 32 MU at 6 MV were studied.
Ground truth values for marker matches
A tool developed in MATLAB was used to obtain the ‘‘ground truth’’ transformation (three 
translations and three rotations) that the SGT matching software should ideally yield. With 
this tool, markers are manually identified in an orthogonal pair of images by clicking on the 
centers of the markers in each image. Given two pairs of orthogonal images and the corre-
sponding manually identified marker positions, the tool calculates the rigid body transforma-
tion between the pairs of images. For each pair of images used, the procedure was repeated 
three times, and the mean transformation was calculated and used as the ground truth.
TCSA precision
The precision of the TCSA was measured using the slab phantom with embedded gold 
markers. Initially, the phantom was placed on the couch, and the absolute 3D position of 
the couch was obtained. Next, two orthogonal kVIs were acquired with the phantom in the 
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initial position. Predetermined displacements ranging from - 2 cm to 2 cm were applied to 
the phantom using couch shifts. After each execution of three random displacements along 
the three orthogonal axes, the absolute position of the couch in the room coordinate system 
was determined. Next, two orthogonal kVIs of the phantom were acquired, and the couch 
was moved back to the initial position. All images were imported into TNT, and the automatic 
SGT marker-matching tool was used to measure the applied displacements by comparing 
the marker positions in each image set with those in the initial reference images. For these 
measurements, the clinically applied TCSA tolerance of 0.3 mm was used. The TCSA will not at-
tempt to improve a deviation between the couch position readout and a prescribed position 
of <0.3 mm. This tolerance setting enables fast convergence toward the prescribed position, 
without oscillations around the optimal position.
Clinical study
The positioning accuracy obtained with SGT was investigated for 10 patients treated with 
SGT during EBRT with three or four implanted markers. The treatment plan beam angle was 
360˚ ± 1˚, 90–93˚, and 264–270˚ for the anteroposterior, left-lateral, and right-lateral direc-
tions, respectively. The dose prescription for 8 of the 10 patients was 72 Gy in 36 fractions at 
2 Gy / fraction. Of the 10 patients, 2, who had previously undergone high-dose-rate brachy-
therapy, were treated with 1.8 Gy in 25 EBRT fractions, and the markers (three or four platinum 
cylinders; 3 mm x 1 mm) implanted during the brachytherapy procedure were used. For all 
patients, pre- and postcorrection kVI/MVI pairs were obtained, and the duration of all involved 
steps was logged. From the outcome of the automatic match in the SGT for these patients, the 
pre- and postcorrection systematic and random errors were calculated. In addition, for each 
fraction, the automatic match results found in the SGT procedure were compared with the 
ground truth values obtained with the tool described in the previous two sections to assess 
the accuracy of SGT positioning during clinical operation.
results
Phantom verification: translations
The kV/MV combination yielded greater marker detection rates than did the MV/MV approach 
because of the greater marker visibility in the lateral kV images (Fig. 4). The success rate was 
calculated as the fraction of automatic matches with a 3D deviation from ground truth of 
<2 mm. Because our goal with SGT was to obtain accuracy better than 2 mm for positioning 
errors, this was a conservative cutoff level. The mean and SD values expressing differences 
between the automated SGT result and ground truth per translation direction are reported in 
Table 1 for each exposure, beam energy, and combination of orthogonal images. In Table 1, 
slightly greater magnitudes of deviations from ground truth values were observed for the low 
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MVI exposures (1–2 MU); this was more so for the MVI/MVI pairs because of the lower image 
quality of the MVI compared with the kVI. This was also reflected in the lower success rate for 
MVI/MVI at the lowest exposures (Fig. 4).
The cumulative frequency distributions per beam energy of all the observed 3D deviations 
between the automated match and ground truth are shown in Fig. 5. From the regular behav-
ior of these distributions, it was apparent that although a cutoff level of 2 mm for success was 
applied, in the small fraction of failure cases, the errors were always <3 mm. The best results 
(steepest descent in cumulative distribution) were obtained for the 18-MV beam.
Phantom verification: combined translations and rotations
Table 2 shows that even for the large combined rotations of ≤ 20˚, the kVI/MVI image pairs 
yielded a success rate of 100% for both studied MVI exposures. The success rate was scored 
as the match results for which the 3D magnitude of the difference with ground truth was <2 
mm for translations and < 2˚ for rotations. For the MVI/MVI image pairs, a 30% decrease in the 
success rate occurred with the lower MVI exposures. The reason for using a low exposure is 
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Figure 4. Image matching success rates (for marker translations) vs. monitor units at three beam energies for a phantom. KV/MV = initial 
stereographic targeting procedure using orthogonal kilovoltage image and megavoltage image combination. MV/MV = procedure using two 
orthogonal megavoltage images.
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1 MU 2 MU 4 MU 8 MU 32 MU
x       y       z x       y       z x       y       z x       y       z x       y       z
MV/MV (mm) (mm) (mm) (mm) (mm)
6 MV
Mean 0.7 0.6 0.6 -0.1 0.9 0.8 0.3 0.6 0.1 -0.1 0.7 -0.1 -0.1 0.6 0.4
SD 0.4 0.9 1.1 0.6 0.7 1.5 0.4 0.3 0.8 0.5 0.2 0.4 0.2 0.3 0.2
10 MV
Mean -0.1 0.5 0.0 0.2 0.4 0.2 -0.1 0.6 -0.1 -0.1 0.6 0.5 -0.1 0.5 0.5
SD 0.7 0.4 1.0 0.6 0.3 0.6 0.5 0.3 0.6 0.5 0.2 0.5 0.2 0.2 0.1
18 MV
Mean -0.2 0.2 0.2 -0.2 0.3 0.5 -0.1 0.4 0.7 -0.1 0.4 0.6 -0.1 0.5 0.4
SD 0.4 0.4 0.6 0.3 0.3 0.4 0.3 0.3 0.2 0.2 0.3 0.3 0.2 0.3 0.2
kV/MV
6 MV
Mean -0.1 0.1 0.6 0.1 0.1 0.6 0.4 0.1 0.5 0.1 0.1 0.6 0.0 0.1 0.6
SD 0.9 0.4 0.2 0.5 0.3 0.2 0.4 0.3 0.1 0.5 0.2 0.1 0.2 0.2 0.1
10 MV
Mean 0.0 -0.1 0.5 0.1 -0.1 0.5 -0.1 -0.1 0.5 -0.2 -0.1 0.6 -0.2 -0.1 0.6
SD 0.7 0.3 0.2 0.7 0.3 0.2 0.4 0.2 0.2 0.4 0.2 0.2 0.2 0.2 0.2
18 MV
Mean -0.2 -0.1 0.3 -0.3 0.0 0.4 -0.2 0.0 0.3 -0.2 0.0 0.3 -0.1 0.1 0.3
SD 0.3 0.2 0.1 0.3 0.2 0.1 0.3 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.1
Table 1. Means and standard deviations (SD) of differences with ground truth for phantom translations at different exposures and beam energies 
in 3 directions (x, y, z). The data is shown for two cases; using both MV/MV and kV/MV image pairs. In the case of MV/MV image pairs, the 
exposure pertains to both images.
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Figure 5. Cumulative frequency distributions of magnitudes of observed three-dimensional position deviations from ground truth as observed in 
experiments with phantom translations. For each energy, curves were constructed from data for all translations and megavoltage image exposures.
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evident; we wanted to deliver no more than a few MUs before correctly positioning the target 
volume. Hence, the combination of kVI and MVI used in SGT is superior to using EPIDs only.
6 MU 32 MU
x       y       z Rx      Ry      Rz x       y       z Rx      Ry      Rz
(mm) (º) (mm) (º)
MV/MV Mean -0.1 0.6 0.1 -0.3 0.2 0.3 0.2 0.5 -0.2 -0.3 0.1 0.3
SD 0.4 0.4 0.7 0.8 0.7 0.6 0.4 0.2 0.3 0.4 0.5 0.4
Success Rate 70 % 100 %
kV/MV Mean 0.0 0.0 0.3 -0.4 0.1 0.1 0.3 -0.1 0.2 -0.4 0.1 0.2
SD 0.4 0.2 0.3 0.6 0.5 0.4 0.3 0.2 0.3 0.4 0.5 0.3
Success Rate 100 % 100 %
Table 2. Differences between SGT and ground truth for two exposures in experiments with combined translations (x, y, z) and rotations (Rx, Ry, 
Rz) using both MV/MV and kV/MV combinations. Success rates are also shown for both image combinations.
TCSA accuracy
As can be seen in Table 3, the precision of the positioning achieved with TCSA was better than 
0.3 ± 0.3 mm (mean ± SD) along all directions. This couch positioning precision was mainly 
limited by the TCSA tolerance setting of 0.3 mm, as well as the couch read-out accuracy.
LR CC AP
(mm) (mm) (mm)
Mean 0.29 0.03 0.23
SD 0.27 0.21 0.28
Table 3. Mean and standard deviations (SD) expressing differences between prescribed and measured couch shifts obtained with the TCSA.
Clinical results
Scatter plots of the deviations between the results obtained in the clinical application of SGT 
and ground truth are shown in Fig. 6. The marker detection success rate for the clinical images 
was 99.6%, with most of the deviations from ground truth <1 mm. The inaccuracy (mean ± SD) 
of the SGT match with respect to the ground truth was 0.2 ± 0.4 mm for the left–right, 0.1 ± 0.5 
mm for craniocaudal, and 0.0 ± 0.4 mm for the anteroposterior direction. Table 4 summarizes 
the results of the measured patient translational and rotational positioning (COM) errors be-
fore and after SGT positioning, accumulated for all treatment fractions. The small residual po-
sitioning errors obtained with SGT included the inaccuracies in the remotely controlled couch 
shifts, inaccuracies in the COM translation obtained from the SGT match, and the intrafraction 
motion during the period between pre- and postcorrection images. Considering only the er-
rors resulting from setup (translation of the COM of the markers), the common equation of 
CTV-PTV margin = 2Σ + 0.7σ (110) resulted in margins >12 mm without SGT and margins of 
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Figure 6. Scatterplots with deviations of prostate setup errors (translational) measured in clinic with stereographic targeting and ground truth 
values obtained in manual off-line analysis. AP = anteroposterior; CC = craniocaudal; LR = left-right.
Translations (mm) Rotations (º)
Σx       Σy        Σz σ x      σ y      σ z ΣRx      ΣRy      ΣRz σ Rx     σ Ry      σ Rz
Pre SGT 1.7 4.1 2.9 1.6 2.7 3.2 4.9 1.3 1.7 4.2 1.6 1.3
Post SGT 0.2 0.5 0.4 0.6 0.7 0.8 5.0 1.4 1.9 3.9 1.6 1.3
Table 4. Measured translational and rotational prostate positioning errors (systematic (Σ) and random (σ)) before and after SGT repositioning.
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Figure 7. Cumulative frequency distribution of three-dimensional center-of-mass displacements of markers for all patients and fractions, before 
and after stereographic targeting (SGT).
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about 2 mm after applying the SGT corrections. A cumulative histogram of 3D translational 
errors (3D vector length) of the COM of the prostate markers for all patients and fractions is 
shown in Fig. 7, in which each 3D error represented the sum of the systematic and random 
error. Before SGT, the observed errors could exceed 10 mm in all directions but were reduced 
to <3 mm after SGT. Furthermore, the procedure was fast. Considering the upper limits of the 
time ranges in Fig. 2 revealed that SGT positioning was performed within 45 s/fraction.
discussion
Using SGT, the systematic and random errors were reduced to 0.5 mm and 0.8 mm (SD), re-
spectively, within 1 min/treatment fraction. The crossfire imaging, accurate automatic match 
with a high success rate (>99%), precise remote couch control system, and integration into 
one software environment are the ingredients that allow for this combination of speed and 
accuracy. Although in this study, the anteroposterior MV beam was used because it is a part of 
our treatment plan, the SGT can be started at any gantry angle. 
Apart from the combined kV/MV imaging, our approach to on-line prostate positioning 
might seem similar to other stereoscopic imaging systems such as the ExacTraC X-ray 6D sys-
tem (BrainLab AG, Heimstetten, Germany) (111-113). The published data on the final accuracy 
and timing achieved for prostate markers are limited, but the findings indicate that SGT is 
at least as accurate as the ExacTraC system (112). A relevant difference is that SGT uses two 
imaging devices that have a use in their own right. The XVI system is also used for cone-beam 
CT acquisition to visualize soft tissues insufficiently visible on planar images (e.g., the seminal 
vesicles and rectum in the case of the prostate). Such information can be used in adaptive 
radiotherapy strategies (114,115). Furthermore, the EPID can be used for position verification 
without an additional kV dose (third to last paragraph before ‘‘Conclusion’’ section), as well as 
for EPID dosimetry (116). Such flexibility is not offered by a dedicated planar imaging system 
such as the ExacTraC. 
The combination of speed and accuracy for prostate positioning with implanted markers is 
hard to match with techniques relying on volumetric imaging alone (117). Cone-beam strate-
gies for the prostate will likely involve offline correction schemes (114,115), partly because 
of the workload, speed, and registration success rate, but also because the kV dose is not 
negligible. Off-line corrections might be less effective for the hypofractionation schemes cur-
rently under study for prostate RT (118,119). 
Although the importance of time trends for prostate targeting has not been fully estab-
lished, a recent fiducial markerbased study indicated that the time trends must be taken into 
account for accurate prostate positioning (Σ <1 mm) with off-line corrections (120). We have 
recently proposed an off-line scheme to deal with the time trends (121). The reduction of sys-
tematic and random positioning errors could be partially achieved with an adaptive strategy in 
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which CT scans acquired during the initial week of treatment are used to estimate patient-spe-
cific PTVs in an off-line manner (115). Nevertheless, systematic and random positioning errors 
of <1 mm (SD), regardless of the time trends, can only be achieved with an on-line approach. 
The potential for planning margins as small as 2 mm when SGT is applied is hampered by 
various factors such as prostate rotation, intrafraction motion, target volume deformation, 
marker migration, and delineation (or generally, target definition) inaccuracies. 
The measured prostate rotations (Table 4) are similar to the values reported in earlier stud-
ies (93,101,122,123). Various studies have shown that the prostate rotates mostly about the 
left–right axis, with the rotation center at the apex (101,124). If the prostate position is cor-
rected according to the COM of the markers, inadequate coverage could occur, especially near 
the base (‘‘undercorrection’’) and apex (‘‘overcorrection’’), dependent on the chosen planning 
margin (101). The measured COM displacements contain a contribution from the rotations, 
and the COM translation corrections are exact only at the COM position. The residual devia-
tions at the prostate boundary depend on the prostate shape and size. For a perfectly spheri-
cal prostate with the marker COM at its center, the COM translation corrections will yield 0 
residual errors along the entire prostate boundary (i.e., each point within the boundary will be 
covered by the boundary after correction), regardless of the rotations. We calculated the re-
quired margins for SGT in the case of the rotations (Table 1) for various prostate shapes, rang-
ing from circular to flattened at the base and sharpened at the apex. We added in quadrature 
post-SGT translational errors and local distances between prostate hulls induced by rotations, 
as given in Table 4, to obtain the effective Σ and σ. Assuming a prostate base–apex length of 
4 cm, application of a margin equation of 2Σ + 0.7σ yielded a maximal CTV-PTV margin of 4 
mm. However, larger displacements can occur at the seminal vesicles, owing to rotations, as 
well as deformations (122,125). We are currently conducting a multiple CT study to investi-
gate the motion of the seminal vesicles and prostate boundary (deformations) with respect 
to fiducial markers. In that study, we have included the residual errors resulting from pros-
tate and seminal vesicle deformation into a population-based margin calculation to obtain 
well-defined margins for SGT. Furthermore, we are presently developing a strategy to correct 
for the rotational positioning errors using on-line selection of an optimal plan matching the 
observed rotation) from a library of plans created for various prostate rotations. Because these 
plans could include seminal vesicle treatment, knowledge of the seminal vesicle motion in the 
presence of rotations is required to create optimally conformal plans. 
Prostate intrafraction motion during EBRT has been well studied (93,102,126,127). We are 
conducting a study on intrafraction motion for prostate cancer patients treated with SGT by 
acquisition of extra kVIs and MVIs during treatment. The initial results have indicated that 
the intrafraction motion is mainly random, with a SD of <1 mm in both the anteroposterior 
and the craniocaudal directions. Hence, the contribution to planning margins will be small 
compared with previously mentioned factors. Because of the speed of the SGT procedure, the 
intrafraction motion between the moment of prostate position measurement and treatment 
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will be minimized and the intrafraction motion could be reduced further by repetition of the 
SGT procedure within one fraction (e.g., before each treatment beam). We are extending SGT 
with a system for continuous automatic detection of intrafraction motion using MVIs of the 
treatment beams (i.e.,without an additional kV dose). 
Marker migration and prostate deformation also contribute to the required planning mar-
gins. Recent studies have shown that the effect of marker migration is quite minimal for the 
prostate, and the overall effect of prostate deformations is <1 mm (122,125). In our study, no 
substantial migration of the markers was observed. 
Finally, to fully use the possibility of margin reduction as a result of the reduction of patient 
positioning errors presented by SGT, one should minimize the delineation errors (122,128,129). 
One can treat delineation errors as one of the sources of systematic errors (129), but care must 
be taken with this approach because delineation errors do not necessarily behave stochasti-
cally. For instance, the prostate volumes on CT tend to be systematically larger than those 
observed on MRI and ultrasonography in transversal slices. However, CT can systematically 
underestimate the volume near the superior and inferior boundaries (130,131). Apart from 
anatomic position, the magnitude of the intermodality and inter- and intraobserver differ-
ences is also dependent
on the exact acquisition and delineation protocols applied. The use of a margin to account 
for small random delineation inaccuracies (e.g., intraobserver delineation errors) is reason-
able. However, for systematic intermodality and interobserver variations, it is a rather crude 
tool. More promising approaches are offered by multimodality imaging and registration, as 
well as flexible delineation tools that allow for contouring in multiple planes simultaneously.
conclusion
We have developed and clinically evaluated a fast and accurate procedure for daily on-line 
repositioning of the prostate using rapid sequential imaging of implanted markers with or-
thogonal kV and MV beams. The procedure is based on fully automated extraction and 3D 
registration of the imaged markers followed by remote couch control translations under 
control within a single software environment. This approach achieved residual systematic and 
random errors of <0.8 mm (SD) in the three principal axes, with an addition of <1 min to the 
treatment time. Furthermore, the procedure limits the imaging-specific dose, because the MVI 
is obtained with the therapeutic dose and the planar kVIs are acquired for only one direction.
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abstract
Purpose
To quantify the residual geometric uncertainties after on-line corrections with intraprostatic 
fiducial markers, this study analyzed the deformation of the prostate and, in particular, the 
seminal vesicles relative to such markers.
Patients and Methods 
A planning computed tomography (CT) scan and three repeat CT scans were obtained for 
21 prostate cancer patients who had had three to four cylindrical gold markers placed. The 
prostate and whole seminal vesicles (clinical target volume [CTV]) were delineated on each 
scan at a slice thickness of 1.5 mm. Rigid body transformations (translation and rotation) map-
ping the markers onto the planning scan positions were obtained. The translation only (Tonly) 
or both translation and rotation were applied to the delineated CTVs. Next, the residue CTV 
surface displacements were determined using nonrigid registration of the delineated con-
tours. For translation and rotation of the CTV, the residues represented deformation; for Tonly, 
the residues stemmed from deformation and rotation. Tonly represented the residues for most 
currently applied on-line protocols. The patient and population statistics of the CTV surface 
displacements were calculated. The intraobserver delineation variation was similarly quanti-
fied using repeat delineations for all patients and corrected for.
Results 
The largest CTV deformations were observed at the anterior and posterior side of the seminal 
vesicles (population average standard deviation ≤3 mm). Prostate deformation was small 
(standard deviation ≤1 mm). The increase in these deviations when neglecting rotation (Tonly) 
was small.
Conclusion 
Although prostate deformation with respect to implanted fiducial markers was small, the 
corresponding deformation of the seminal vesicles was considerable. Adding marker-based 
rotational corrections to on-line translation corrections provided a limited reduction in the 
estimated planning margins. 
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introduction 
Prostate cancer is the most common type of cancer for men in Western countries (82) and is 
often treated with external beam radiotherapy (EBRT). However, external beam radiotherapy 
leads to Grade 2 late gastrointestinal toxicity in 1.6–32% of patients, Grade 2 late urinary 
toxicity in 15–41%, and erectile dysfunction in 36–43% (5,12,81). Therefore, a large patient 
population would benefit from techniques able to reduce these common sequelae.
Apart from imperfect target delineation, several uncertainties exist regarding movement 
of the clinical target volume (CTV), CTV deformation, and variations in beam geometry char-
acteristics. A margin is added to the CTV to account for these uncertainties. The planning 
target volume (PTV) is the CTV plus this margin (2). A reduction of the CTV-PTV margin can 
lead to lower toxicity (132). The CTV-PTV margin can be reduced to less than the commonly 
used 1 cm with image guided radiotherapy (IGRT) or adaptive radiotherapy (101,115,133).
In our clinic a fully automated method for fast and accurate daily on-line prostate position-
ing during external beam radiotherapy was developed for the Synergy system (Elekta, Crawley 
UK) and clinically implemented (133). This method, Stereographic Targeting (SGT), is based on 
intraprostatic fiducial markers that are imaged in a crossfire of megavoltage and kilovoltage 
beams, followed by fully automated image analysis and remotely controlled couch shifts. De-
spite a high positioning accuracy for the center of mass (COM) with SGT, the margin reduction 
must be based on knowledge of the residue displacements over the entire surface of the CTV. 
In this study, the residue displacements were obtained from repeat computed tomogra-
phy (CT) scans delineated at a high resolution after rigid registration of the fiducial markers 
by using non-rigid registration. Quantification of these residues allows for the assessment 
of margins for markerbased setup corrections. For instance, the marker registration method 
allowed us to quantify the residue displacements when only translation corrections were ap-
plied. The latter displacements depend not only on the CTV-shape but also on the behavior 
of the seminal vesicle deformation in the presence of prostate rotations. Knowledge of these 
displacements is clinically relevant because on-line corrections are often limited to transla-
tion corrections (112,133). To our knowledge, this is the first study to quantify these rotation 
deviations in detail.
The use of fiducial markers as a reference frame in this study had another major advantage: 
the markers are clearly distinguishable on the CT scans and their relative positions are very 
stable (101,120). In contrast to methods that use delineated CTVs for initial rigid body registra-
tion (134), the rigid body match with markers hardly depends on the sought deformations or 
on the delineation errors. Therefore, fiducial markers present a suitable frame of reference for 
quantifying the deformations.
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Patients and methods 
Patients
Patients scheduled for external beam radiotherapy for prostate cancer were asked to partici-
pate in this study (i.e., undergo multiple CT scan sessions). Between August 2006 and March 
2007, 21 patients agreed to participate and gave written informed consent. The clinical T 
category was as follows: Stage T1, 9 patients; T2, 5 patients; and T3, 7 patients. Patients with T3 
tumors were treated with adjuvant hormonal therapy. Although not all patients were treated 
to the seminal vesicles, the whole seminal vesicles were analyzed for each patient in this study.
In each patient three to four fiducial markers (gold cylinders, 1 mm × 5 mm) were implant-
ed transperineally using 18 gauge needles under transrectal ultrasound guidance and local 
anesthetic. The Medical Ethical Committee of our hospital approved the study, which was 
conducted in accordance with the Declaration of Helsinki.
Data acquisition
For the planning CT scan, the patients followed our routine clinical protocol. The planning 
CT scan (Somatom Sensation Open with HiRes-option, Siemens Medical Solutions, Erlangen, 
Germany) was scheduled ≥1 week after marker implantation to allow any possible edema to 
resolve. Patients used a laxative and were instructed to empty their rectum before the plan-
ning CT scan. Furthermore, they were instructed to empty their bladder and drink 0.5 L of fluid 
1 h before the planning CT scan. In treatment weeks 2, 4 and 6 a repeat CT scan was acquired 
directly before or after a treatment fraction. Patients followed the same instructions, except 
for the use of a laxative.
All four scans were performed with the patient set-up as during treatment (supine posi-
tion, head rest, and knee support and feet support). The CT scans were reconstructed with a 
slice thickness of 1.5 mm and a transversal pixel size of 0.7 × 0.7 mm2.
The prostate and the whole seminal vesicles (CTV) were delineated on each CT scan by a 
single observer (G.J.W.) at the same slice resolution (1.5 mm). The distance from the inferior-
most fiducial marker to the apex of the prostate from the planning CT scan was used as a 
guide to identify the apex on the repeat CT scans.
Analysis
The analysis was performed using in-house developed software (C++ using the itk/vtk toolkits 
and Matlab). Surface meshes were created from the Digital Imaging and Communications 
in Medicine (DICOM) exported contours. Hereafter, the CTV surface is referred to as the CTV 
and any quantity obtained from the planning and repeat CT scan is termed “reference” and 
“repeat”, respectively.
The rigid body transformation between the repeat and reference scans was obtained with 
a dedicated tool. A single marker was defined by the two longitudinal end positions of each 
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marker. In each repeat scan, the markers were identified and a rigid body transformation solv-
ing for translation and rotation about the COM of all markers, was performed. This transforma-
tion was then applied to the repeat CTV.
Next, the residual deformation between the repeat and reference CTV was estimated by 
non-rigid registration, see Chui and Rangarajan and Vasquez Osorio et al. (135-137) for details. 
The nonrigid registration finds a transformation function between two point sets derived 
from the CTV meshes.   Then, the transformation function generated vectors that connect 
the points on the repeat CTV to the reference CTV.  These vectors are referred to as “residue 
displacements”.
For each patient, the residue displacements were used to create an average CTV shape and 
the standard deviations (SDs) of the vector field-projections on the local surface normals were 
derived. We restricted ourselves to reporting motion along these normals because such mo-
tion is the most relevant to determine CTV coverage and required margins. To calculate and 
visualize the population statistics, the same nonrigid transformation software was used to 
create the population average CTV and to map patient specific local SDs onto the population 
average CTV. The procedure, described in detail in the Appendix, is illustrated in Fig. 1.
 






Figure. 1. Light gray shapes represent rigidly registered clinical target volumes (CTVs). Subsequent nonrigid registration yielded average CTV 
for each patient (dark gray) and corresponding interfraction standard deviations of deformations. Patient-specific standard deviations are then 
projected on population average CTV (black).
Correction for delineation variation
The SDs described in the previous section might have been overestimated, owing to delinea-
tion inaccuracies. Because all scans were delineated by a single observer (G.J.W.) and because 
only variations from scan to scan determined the SDs, the overestimate resulted from to in-
traobserver variation. Hence, two repeat scans in each patient were recontoured by the same 
observer (G.J.W.). The same non-rigid matching was applied to register Delineation 1 onto 
Delineation 2. The length of the subsequent deformation vectors was taken in quadrature 
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and averaged for both re-delineated scans to estimate the local SDs due to the delineations. 
Because these SDs comprise the inaccuracies in both delineations, they were divided by √2 
to obtain the single delineation SD. The latter SDs were subtracted in quadrature from the 
deformation SDs to obtain the actual CTV shape variations.
Full correction vs. translation only correction
Large systematic and random rotations of the prostate about the left-right axis have been 
observed (SD = 4-5°) when only translational corrections are applied (101,120,123). 
To study the residue displacements due to rotations and deformations in the case of trans-
lational corrections determined from the markers’ COM, we repeated the nonrigid registration 
analysis after only the translation part of the rigid body transformation (Tonly) was applied to 
the CTVs. The effect of the rotations in a Tonly correction protocol can increase if the COM of the 
markers is not coincident with the prostate COM (101). Because we used marker-based COM 
translations for registration, this effect was implicitly taken into account in our study.
Separation into systematic and random residue displacements
The SDs described in the previous section reflect the interfraction variation of residue displace-
ments at the CTV surface. Interfraction variations are commonly referred to as random errors 
and are usually denoted by σ (138). If the displacements have no systematic time dependency 
during the treatment course (i.e., it is unimportant when the planning and repeat CT scans 
are obtained), then the SD of systematic errors, Σ, equals the SD of the random errors: Σ = σ 
(115,138). The number of scans and patients in this study was too small to test this assumption 
in detail. Nevertheless, if Σ is locally significantly smaller or larger than σ, this should be taken 
into account in the margin calculations. We, therefore, investigated whether we could find 
large deviations from Σ = σ. The calculation of the Σ -maps is described in the Appendix.
results
Marker registration results and accuracy
The rigid body registration on fiducial markers determined the frame of reference in this 
study. We, therefore, determined the accuracy of this registration method. After registration, 
the match gives the remaining displacements for each marker. The SD of these displacements 
for all registrations was 0.4 mm in each direction. This SD included all deviations in the reg-
istration process, such as the accuracy of defining markers on the CT scans and the relative 
displacements of the markers. Consistent with the published data, these effects are small 
(101,120) and the assumption that the markers provide a proper frame of reference was thus 
confirmed. The SD for the COM position was 0.2 mm, equal to the accuracy of the translation 
part of the rigid body transformations we applied. 
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The SDs of the systematic (Σ) and random (σ) prostate rotation angles were approximately 
4° about the left-right axis and <2° about the other axes. The average measurement inac-
curacy of these rotations, calculated from the marker separations and the above-mentioned 
residue errors (0.4 mm SD) for each marker, was < 1° (SD).
Residue interfraction displacements due to deformations and rotations
Figure 2 and Tables 1 and 2 summarize the residue displacements along the local surface 
normals, as obtained for the translation plus rotation (T+R) (residues due to deformation) and 
Tonly (residues due to both deformation and rotation). Tables 1 and 2 list the average residue 
displacements of the different regions. Figure 2a shows the maps of the population averaged 
SDs (σ, see Appendix) of the residue displacements, uncorrected for delineation variation, 
along the CTV surface normals, projected onto the population average CTV shape in the case 
of T+R.
Tables 1 and 2 and Fig. 2b summarize the intraobserver delineation variation. This small 
variation was comparable for the prostate and seminal vesicles. Correcting the full variation 
for intraobserver variation, yielded the actual variation, as listed in Tables 1 and 2 and dis-
played in Fig.2c, 2d. The effect of the intraobserver correction was small. The actual varia-
tion for case T+R reflects the interfraction motion of the CTV surface relative to the fiducial 
markers. Apparently, the prostate surface moves along with the fiducial markers as an almost 
fully rigid body (SDs ≤1 mm). In contrast, the seminal vesicles exhibited considerable relative 
motion. For the seminal vesicles, the SDs ranged ≤ 3 mm and was dependent on the position.
Left Right Cranial Caudal Anterior Posterior
Full variation, 
T + R
0.5 0.6 1.2 1.0 1.0 1.0
Intraobserver variation, 
T + R
0.4 0.5 0.3 0.4 0.7 0.5
Actual variation, T+ R 0.3 0.3 1.1 0.9 0.7 0.8
Actual variation, Tonly 0.3 0.3 1.4 0.9 0.7 1.3
Table 1. Standard deviations (σ) for deviations along local surface normals in various regions of interest of prostate
Abbreviations: T + R = correction for rotation and translation; Tonly = correction for translation only
Influence of rotations on residue displacements
When only the translation correction for the markers’ COM was applied, we obtained the SD 
maps (Fig. 2d and the last rows of Tables 1 and 2). For the prostate, the residue displacements 
for Tonly became slightly larger cranially and posteriorly with respect to T+R. These local in-
creases were as expected, because the average prostate shape (Fig. 2) was most flattened in 
these regions (for a perfectly spherical prostate with the marker COM at its center, the increase 
would be zero).
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Similarly, the residue displacements for the seminal vesicles increased for Tonly. Hence, the 
vesicles co-rotated with the prostate to a certain extent. Nevertheless, owing to the large 
deformation of the vesicles relative to the markers, the relative influence of the rotations on 
residue displacements was small (everywhere < 0.7 mm).
    
    
    
      




Figure 2. (a) Standard deviation of interfraction variation (σ) after marker-based rigid body registration (translation plus rotation [T+R]), as 
projected onto the population-averaged clinical target volume, uncorrected for intraobserver delineation variation. (b) Corresponding standard 
deviations of intraobserver delineation variation. (c) Same as in Fig. 2a, but now corrected for delineation variation in Fig. 2b (i.e., actual 
variation). (d) Same as Fig. 2c, but now for only rigid translation applied (Tonly).
(a)
(b)
(c)
(d)
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Systematic and random residue displacements
The residues in Fig. 2 were random interfraction displacements. Figure 3 shows the abso-
lute values of the difference of the systematic (Σ) and random (σ) residue displacements as 
mapped onto the average CTV shape. The smallness of this difference (everywhere < 0.7 mm, 
and usually < 0.5 mm) was consistent with the assumption that Σ = σ. Hence, the CTV defor-
mations with respect to the markers can be considered to be equal in the planning and repeat 
CT scans.
      
Figure 3. Absolute values of the difference of the systematic (Σ) and random (σ) residue displacements, projected onto the population-averaged 
clinical target volume.
discussion 
The most detailed previous study on prostate and seminal vesicle deformation was by Deur-
loo et al. (134), who quantified the shape variations of the prostate and seminal vesicles by 
using repeat CT scans. Apart from the use of thicker CT slices than in the present study (3 mm 
vs. 1.5 mm), an important distinguishing feature was their initial rigid body transformation. 
This transformation was obtained from a chamfer match of the entire delineated gross tumor 
Lateral 
left SV
Lateral 
right SV
Tip left 
SV
Tip right 
SV
Anterior 
left SV
Anterior 
right SV
Posterior 
left SV
Posterior 
right SV
Full variation, 
T+ R
2.0 1.8 2.2 2.6 2.4 2.5 2.6 2.8
Intraobserver 
variation, T + R
0.8 0.9 0.7 0.7 0.3 0.3 0.4 0.6
Actual variation,    
T + R
1.7 1.6 2.1 2.5 2.3 2.5 2.5 2.7
Actual variation, 
Tonly
1.7 1.7 2.2 2.7 2.8 2.9 3.1 3.4
Table 2. Standard deviations (σ) for deviations along local surface normals in various regions of interest of seminal vesicles
Abbreviations: SV = seminal vesicle; other abbreviations as in Table 1.
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volume (prostate and vesicles). Therefore, the deformation might have influenced their rigid 
body transformations. For Deurloo et al. this problem was not as relevant, because their study 
considered residue displacements in correction strategies based on prostate delineations 
from multiple CT scans. However, when using prostate markers for the rigid body registra-
tion, the actual shape variation near the seminal vesicles is expected to be greater than that 
derived in their approach. Indeed, Deurloo et al. obtained an average SD of 1.5 mm near the 
seminal vesicle tips. In contrast, we obtained 2.3 mm, and even larger SDs posteriorly (2.6 
mm, Table 2). Consequently, for marker based correction strategies, the larger numbers for 
the seminal vesicles presented in this report might apply. The small prostate deformation 
reported by Deurloo et al. is very similar to the findings of the present study.
Meijer et al. (139) presented a repeat CT scan study with intraprostatic fiducial markers. The 
prostate and the first 2 cm of the seminal vesicles were included in the CTV. The results were 
reported in terms of the local planning margins for various correction strategies instead of lo-
cal deformations. Consequently, these derived planning margins pertain to their specific dose 
distributions. Their result that perfect online set-up corrections based on markers allowed for 
margins of 3 mm for the prostate and 7 mm for the first 2 cm of the vesicles is consistent with 
the margins we derived in the next paragraph.
The planning margin calculation in the presence of deformations is a non-trivial subject. 
Margin recipes such as the CTV-PTV margin = 2Σ+ 0.7σ (110) were derived for rigid body trans-
lation motions (110,140), in which the values of Σ and σ are constant along the surface of the 
CTV, together with assumptions on the dose distribution. Such recipes are already approxi-
mate and somewhat arbitrary for ideal cases (110,140). To discuss the full effect of non-rigid 
motion on planning margin estimates was beyond the scope of this study. For delineation 
errors, which can be considered to be small deformations, because they can be different at 
each point on the CTV surface, it has been suggested that a margin recipe such as given above 
is still approximately valid (140). Therefore, purely for illustrative purposes, we estimated the 
margins by applying local values of Σ and σ along the surface normals in a margin recipe. The 
thus-obtained margins in the case of on-line correction by SGT are shown in Fig. 4, for transla-
tion corrections (Tonly) and translation plus rotation corrections (T+R). The corresponding resi-
due displacements as reported in this study were added in quadrature to the Σ and σ values 
of COM displacements remaining after SGT correction (141). The latter contribution consisted 
of the small residue errors (Σ ≤ 0.5 mm, σ ≤ 0.8 mm in each direction) directly after on-line 
correction (133) as well as those caused by intrafraction motion. Kotte et al. (142) performed 
a markerbased study on prostate intrafraction motion in 427 patients. We took the values 
from their Table 2 (Σ ≤ 0.6 mm, σ ≤ 0.9 mm in each direction), consistent with the results we 
obtained in a smaller group. Furthermore, the presently unavoidable random intraobserver 
delineation errors (Fig. 2b) satisfied the criteria for inclusion in a CTV-PTV margin expansion, 
and were included in the margin calculation.
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The decrease in margins when adding on-line (markerbased) rotation corrections was 
modest (Fig. 4b). For the prostate, this decrease was negligible, but for the vesicles it was 
approximately 1 mm. This small reduction was expected because the vesicles only partly co-
rotated with the prostate.
 
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Figure 4. Local clinical target volume to planning target volume margins derived for on-line correction strategies, projected onto the population-
averaged clinical target volume. (a) Only translation corrections (Tonly). (b) Translation and prostate rotation corrections (T+R).
Despite the small residue errors near the prostate the margins for the seminal vesicles could 
not be reduced much <1 cm. However, Fig. 4 shows that when anisotropic margins would 
be used an additional reduction could be made at the lateral part of the seminal vesicles. 
The seminal vesicles seemed to deform mostly in the anterior-posterior and cranial-caudal 
direction because of variation in rectal and bladder filling. In this study, a mild laxative was 
only used before the planning CT scan. The use of a mild laxative to promote an empty rectum 
during treatment (if no diarrhea is present), might enable an additional reduction of the treat-
ment margin, especially for the seminal vesicles.
Nonetheless, these results stemmed from the mainly geometrical considerations under-
lying the margin recipes. In particular for the seminal vesicles, it is unclear whether such 
relatively large margins need to be applied. Even a risk of seminal vesicle invasion is pres-
ent, it might not be necessary to guarantee full-dose coverage for the entire seminal vesicle 
volume. However, only one study has provided quantitative information on seminal vesicle 
(a) (b)
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involvement. Kestin et al. (143) analyzed 334 Stage T1 and T2 prostatectomy specimen. Of the 
51 patients with seminal vesicle invasion, only 10% had tumor beyond the proximal 2.0 cm. 
They advised treating the seminal vesicles only in patients with sufficient expected risk and 
to include only the first 2.0 – 2.5 cm of the seminal vesicles in the CTV. However, no evidence 
has been provided to support the inclusion of only a part of the seminal vesicles in the CTV 
for Stage T3-T4 tumors.
Geometrical considerations alone are too limited to predict the clinical effect of margin 
and volume reductions at the seminal vesicles. Factors such as tumor clonogen density and 
characteristics, dose fractionation and the conformality of the dose distribution should be 
taken into account (144). We, therefore, are conducting a study, using the deformation data 
presented in the present study, to validate the planning margins for the prostate and in par-
ticular, the seminal vesicles in a full (radiobiologic) dose reconstruction.
conclusion
The deformation of the prostate relative to the intraprostatic fiducial markers was small (SD 
< 1 mm). In contrast, the deformation of the seminal vesicles relative to these markers was 
significant (SD ≤3 mm). Consequently, the effect on treatment planning margins of the correc-
tions for prostate rotation was small. Future work, including actual dose distribution analyses, 
is required to conclude whether the CTV-PTV margin of the seminal vesicles can be reduced 
significantly less than the commonly used 1 cm for online set-up corrections based on fiducial 
markers. 
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Appendix: Derivation of local systematic and random residue displacements after rigid body registration 
 
I  ch ti nt i PNi 1 ), prostate and seminal vesicles were delineated in each CT scan j ( SNj 1 ; j = 1 
is a reference scan). The so obtained CTV surface meshes jiS , can be represented as a collection of jiN ,  3D 
vectors )(, kr ji
 , each vector representing a surface point:  
 
 )}(,...,)1({ ,,,, jijijiji NrrS
 ; 3, (.) jir .   (1) 
 
Each repeat scan (j > 1) is rigidly registered with scan 1 using the fiducial markers. As mentioned in the 
manuscript, two cases were studied: 
 
a) apply only the translation  
   TSS jijit  ,,  
 
b) apply both translation and rotation   
   TRSS jijit  ,,  
 
The analysis will continue with the rigidly transformed surfaces, jitS , , which are now in the marker-based 
coordinate frame of the reference surface. We will henceforth drop the superscript “t” for readability. 
 
Calculating patient average displacement vectors and average surface 
For patient i and scan j, non-rigid transformations jif , (j > 1) mapping the points of reference surface 1,iS  to 
points on  repeat surface  jiS ,  were obtained using the thin plate spline -robust point matching method. This 
method solves for both the transformation as well as the point-to-point correspondence between the surfaces 
(135,137). We assessed the accuracy of this method as follows. The inaccuracy in the non-rigid registration can 
be expressed as  the distance between the target and deformed surfaces: jiijiji SSfe ,1,,, )(   on each 
surface point. The average value over all patients (i), scans (j > 1) and surface points of the 3D vector length of 
jie ,  was 0.45 mm (SD 0.25mm). Hence, the surface mapping was very accurate for both prostate and seminal 
vesicles. Note however, that this mapping accuracy is not necessarily the same as the accuracy of the anatomical 
correspondence between mapped points. The latter cannot be derived from CT data alone. 
 With these transformations, we obtain the residue displacement vector fields  
 
)}(,),2(),1({)( 1,,,,1,1,,, ijijijiiijiji NSSf     (2) 
 
where the notation for jiv ,  is the same as for jiS , in Eq. (1). Note that, because 1,1,1, )( iii SSf  , we have 
01, iv . Also, each matrix jiv ,  for patient i has the same number of columns 1,, iji NN   
The average surface aiS ,  of patient i is obtained from 
), r state and seminal vesicles wer  delineated in each CT scan j (
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Each repeat scan (j > 1) is rigidly registered with scan 1 using the fiducial markers. As mentioned in the 
manuscript, two cases were studied:
a) apply nly the translation 
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Construction of the population averaged CTV surface (popCTV)  
A specific patient average shape is chosen ( aS ,1 ) and non-rigid transformations { iF } from aS ,1  to aiS ,  are 
obtained. Similar to Eq. (2), the vector fields iV that map the average surface of patient 1 onto that of patient i 
)1( PNi   are   
 
 aaiii SSFV ,1, )(         (4) 
 
Again, 01 V  by definition. The popCTV surface is obtained as 
 
 avgaAVG VSS  ,1       (5) 
 
where avgV  is the average over i of the fields }{ iV . 
 
Patient specific systematic and random residue displacements 
At each point k )1( 1,iNk   spanning the average surface aiS , of patient i, the systematic displacement )(kni  
along the surface normal )(kni
 , was obtained from  
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The corresponding SDs of random displacements along the surface normals, )(kni , were calculated using,  
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Population systematic and random residue displacements 
The systematic and random residue displacements defined in Eq. (6) resp. (7) are defined on the surface points 
of each patient specific average CTV surface aiS , . We can map these points onto popCTV using the non-rigid 
transformation of Eq. (4). Thus, we obtain PN values of ni  and ni at each point spanning popCTV. The 
population random displacement σ is calculated by taking the root mean square average of the PN  patient 
specific random errors n  at each point on the popCTV surface.  
Although ni  is an unbiased estimator of the systematic displacement for patient i, its standard deviation, SD( ni ) 
slightly overestimates Σ due to a contribution by the random displacements for a finite number of scans ( SN ): 
)1/()( 222  Sni NSD   (see (145)). Using σ, this bias was corrected for. Thus obtained maps of Σ and σ 
were used in figures 2-4.
Construction of the population averaged CTV surface (popCTV) 
A specific patient average shape is chosen ( aS ,1 ) and non-rigid transformations { iF } from aS ,1  to aiS ,  
are obtained. Similar to Eq. (2), the vector fields iV that map the average surface of patient 1 onto that of 
patient i 
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populatio  random displacement σ is calculated by taking the root mean squ re verage of the PN  patient 
specific random errors n  at each point on the popCTV surface.  
Although ni  is  unbiased estimator of the systematic displac ment for patient i, its standard deviation, SD( ni ) 
lightly overestimates Σ due to a contribution by the random displacements for a finite number of scans ( SN ): 
)1/()( 222  Sni NSD   (se  (145)). Using σ, this bias was corrected for. Thus obta ned maps f Σ and σ 
were used in figures 2-4.
where avgV  is the average over i of the fields }{ iV .
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Construction of the population averaged CTV surface (popCTV)  
A specific patient average shape is chosen ( aS ,1 ) and non-rigid transformations { iF } from aS ,1  to aiS ,  are 
obtained. Similar to Eq. (2), the vector fields iV that map the average surface of patient 1 onto that of patient i 
)1( PNi   are   
 
 aaiii SSFV ,1, )(         (4) 
 
Again, 01 V  by definition. The popCTV surface is obtained as 
 
 avgaAVG VSS  ,1       (5) 
 
where avgV is the average over i of the fields }{ iV . 
 
Patient specific systematic and random residue displacements 
At each point k )1( 1,iNk   spanning the average surface aiS , of patient i, the systematic displacement )(kni  
along the surface normal )(kni
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The corresponding SDs of random displacements along the surface normals, )(kni , were calculated using,  
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Population systematic and random residue displacements 
The systematic and random residue displacements defined in Eq. (6) resp. (7) are defined on the surface points 
of each patient specific average CTV surface aiS , . We can map these points onto popCTV using the non-rigid 
transf rmation of Eq. (4). Thus, we obtain PN valu s of ni  and ni at each point s anning popCTV. The 
population random displacement σ is calculated by taking the root mean square average of the PN  patient 
specific random errors n  at each point on the popCTV surface.  
Although ni  is an unbiased estimator of the systematic displacement for patient i, its standard deviation, SD( ni ) 
slightly overestimates Σ due to a contribution by the random displacements for a finite number of scans ( SN ): 
)1/()( 222  Sni NSD   (see (145)). Using σ, this bias was corrected for. Thus obtained maps of Σ and σ 
were used in figures -4.
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Construction of the population averaged CTV surface (popCTV)  
A specific patient average shape is chosen ( aS ,1 ) and non-rigid transformations { iF } from aS ,1  to aiS ,  are 
obtained. Similar to Eq. (2), the vector fields iV that map the average surface of patient 1 onto that of patient i 
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Again, 01 V  by definition. The popCTV surface is obtained as 
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Population systematic and random residue displacements 
The systematic and random residue displacements defined in Eq. (6) resp. (7) are defined on the surface points 
of each patient specific average CTV surface aiS , . We can map these points onto popCTV using the non-rigid 
transformation of Eq. (4). Thus, we obtain PN values of ni  and ni at each point spanning popCTV. The 
population random displacement σ is calculated by taking the root mean square average of the PN  patient 
specific random errors n  at each point on the popCTV surface.  
Although ni  is an unbiased estimator of the systematic displacement for patient i, its standard deviation, SD( ni ) 
slightly overestimates Σ due to a contribution by the random displacements for a finite number of scans ( SN ): 
)1/()( 222  Sni NSD   (see (145)). Using σ, this bias was corrected for. Thus obtained maps of Σ and σ 
were used in figures 2-4.
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Population systematic and random residue displacements 
The systematic and random residue displacements defined in Eq. (6) resp. (7) are defined on the surface points 
of each patient specific average CTV surface aiS , . We can map these points onto popCTV using the non-rigid 
transformation of Eq. (4). Thus, w  obtain PN valu s of ni  and ni at each point span ing popCTV. Th  
population random displacement σ is calculated by taking the root mean square average of the PN  patient 
specific rando  errors n  at each point on the popCTV surface.  
Although ni  is an u biase  estimator of the system ic displacement for patient i, it  standard deviati n, SD( ni ) 
slightly overestimates Σ due to a cont ibution by the random displacements for a finite number of sc ns ( SN ): 
)1/()( 222  Sni NSD   ( e (145)). Using σ, this bias was corrected for. Thus obtained maps of Σ and σ 
were ed in figures 2-4.
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Construction of the population averaged CTV surface (popCTV)  
A specific patient average shape is chosen ( aS ,1 ) and non-rigid transformations { iF } from aS ,1  to aiS ,  are 
obtained. Similar to Eq. (2), the vector fields iV that map the average surface of patient 1 onto that of patient i 
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Again, 01 V  by definition. The popCTV surface is obtained as 
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Population systematic and random residue displacements 
The systematic and random residue displacements defined in Eq. (6) resp. (7) are defined on the surface points 
of each patient specific average CTV surface aiS , . We can map thes  points onto popCTV using the non-rigid 
transformation of Eq. (4). Thus, we obtain PN values of ni  and ni at each point spanning popCTV. The 
population rando  displacement σ is calculated by taking th  root mean square average of the PN  patient 
specific random errors n  at each point on the popCTV surface.  
Although ni  is an unbias d estimator of the systematic dis lacement for patient i, its standard deviation, SD( ni ) 
slightly overestimates Σ due to a contribution by the random displacements for a finite number of scans ( SN ): 
)1/()( 222  Sni NSD   (see (145)). Using σ, this bias w s corrected for. Thu  bt ined maps of Σ and σ 
were used in figures 2-4.
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Construc o  of the population averaged CTV surf ce (p pCTV)  
A specific pat ent average shape is chosen ( S ,1 ) and non-rigid transformati ns { iF } from aS ,1  t  aiS ,  are
obtained. Similar to Eq. (2), the vector fields iV that ma  the average surface of patient 1 onto that of patient i 
)1( PNi   are   
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Again, 01 V  by definition. The popCTV surface is obtained as 
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Population systematic and random r sidue displacements 
The systematic and random residue displacements d fined in Eq. (6) resp. (7) are defined o  the surface points 
of each patient specific average CTV surface aiS , . e can map these points onto popCTV using the non-rigid 
transformatio  f Eq. (4). Thus, we obtain PN values of ni  and ni at each point spanning popCTV. The
populatio  random displacement σ is calculated by taking the root mean squ re verage of the PN  patient 
specific random errors n  at each p i t on the popCTV surface.  
Although ni  is an unbiased estimator of the systematic displace ent for patient i, its standard deviation, SD( ni ) 
slightly overestimate Σ d e to a contributi n by the random displacements  a fin te number of scans ( SN ): 
)1/()( 222  Sni NSD   (see (145)). Using σ, this bias was corrected for. Thus obtained maps of Σ and σ 
were used in figures 2-4.
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The systematic a d random residue displacements defined in Eq. (6) resp. (7) are defined on he surface 
points of each patient specific average CTV surface aiS , . We can map these points onto popCTV using 
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 avgaA G VSS  ,1       (5) 
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The corresponding SDs of rando  displacements along the surface normals, )(kni , were calculated using,  
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Population system tic and random resi ue displacements 
The system tic and random resi ue displacements d fined in Eq. (6) resp. (7) are defined on the surface points 
of ach patient specific v rage CTV urface aiS , . We can map these points onto popCTV using the non-rigid
transforma io  of Eq. (4). Thus, we obtain PN values of i and ni  each int spanning popCTV. The 
populatio  rando  displacement σ is calculated by taking the root mean squ re v rage of the PN  patient 
specific random errors n  t each p i t on the popCTV surface.  
Although n  is an unbiased estimator f the systematic displacement for patient i, its st ndard deviation, SD( ni ) 
slightly overestimates Σ due to a contribution by the rando  displacements for a fi ite number of scans ( SN ): 
)1/()( 222  Sni NSD   (see (145)). Using σ, this bias was corrected for. Thus obtained maps of Σ and σ 
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Construction of the opulation averaged CTV surface ( opCTV)  
A spe ific patient average shape is chosen ( aS ,1 ) and on-rig d transformations { iF } from aS ,1  to aiS ,  are 
obtained. Similar to Eq. (2), the vector fields iV that map the average surface of patient 1 onto that of patient i 
)1( PNi   are   
 
 aaiii SSFV ,1, )(         (4) 
 
Again, 01 V  by defin tion. The opCTV surface is obtained as 
 
 avgaAVG VSS  ,1       (5) 
 
wh r avgV  is the average over i of the fields }{ iV . 
 
Patient spe ific ystematic and random residu  displacements 
t ch point k )1( 1,iNk   spanni g th  average surf ce aiS , of patient i, the ystematic displacement )(kni  
along the surface normal )(kni
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The corresponding Ds of random displacements along the surface normals, )(kni , w r  calculated using,  
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Population ystematic and random residue displacements 
The ystematic and random esidue di placements defined in Eq. (6) resp. (7) are defined on the surface points 
of each patient spe ific averag  CTV surface aiS , . We can map th se points onto opCTV using the on-rig d 
transform io  of Eq. (4). Thus, we obtain PN values of ni  and ni at each point spanni g opCTV. The 
opulation random displacement σ is calculated by taking the root mean square average of the PN  patient 
spe ific random errors n  at each point on the opCTV surface.  
Although ni  is an unbiased estimat r of the ystematic displacement for patient i, ts tandard eviation, SD( ni ) 
slightly ov r stimates Σ due to a contribution by the random displacements for a fin te number of scans ( SN ): 
)1/()( 222  Sni NSD   (see (145)). Using σ, this bias was corrected f r. Thus obtain d maps of Σ and σ 
w r  used in figures 2-4.
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Construction of the population averaged CTV surface (popCTV)  
A specific patient average shape is chosen ( aS ,1 ) and non-rigid transformations { iF } from aS ,1  to aiS ,  are 
obtained. Similar to Eq. (2), the vector fields iV that map the average surface of patient 1 onto that of patient i 
)1( PNi   are   
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Again, 01 V  by definition. The popCTV surface is obtained as 
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where avgV  is the average over i of the fields }{ iV . 
 
Patient specific systematic and random residue displacements 
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The corresponding SDs of random displacements along the surface ormals, )(kni , were calculated using,  
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Population systematic and random residue displacements 
The syste atic and random residue displacements defined in Eq. (6) resp. (7) are defined on the surface points 
of each patient specific average CTV surface aiS , . We can map these points onto popCTV using the non-rigid 
transformation of Eq. (4). Thus, w  obtain PN values of ni  and ni at each poi t sp nni g popCTV. The 
population random displacement σ is calculated by taking the root mean square average of the PN  patient 
specific random er or n at e ch point on the popCTV surface. 
Although ni  is an u biased estim tor of the systematic displacement for patient i, its s andard deviation, SD( ni ) 
slightly overestimates Σ due t  a contribution by the random displacements for a finite number of scans ( SN ): 
)1/()( 222  Sni NSD   (see (145)). Using σ, this bias was correc ed for. Thus obt ined maps of Σ a d σ 
were us d in figures 2-4.
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Construction of the population averaged CTV surface (popCTV)  
A spec fic pa ient average shape is chosen ( aS ,1 ) and non-rigid transformations { iF } from aS ,1  to aiS ,  are 
obt ined. Similar to Eq. (2), t e vector fields iV th t map the average surface o  patient 1 nto th t of pat ent i 
)1( PNi   are   
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Again, 01 V  by definition. The popCTV surface is obtained as 
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where avgV  is the aver ge o er i of the fields }{ iV . 
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The corresponding SDs of random displacements along the surface normals, )(kni , were calculated using,  
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Population systematic and random residue displacements 
The systematic and random residue displacements defined in Eq. (6) resp. (7) are defined on the surface points 
of each p ent specific ver ge CTV surfac  iS , . W  can map th e points onto popCTV using the non-rigid 
transformation of Eq. (4). Thus, we obt in PN values of ni  and ni at each point spa ning popCTV. The 
population random di placement σ is calc lated by taking the root mean square average of the PN  patient 
specific random errors n  t ach point on the popCTV surface.  
Alth ni  is an unbiased estimator of the sy tematic d splac men for patient i, its standard deviation, SD( ni ) 
lightly overestim t  Σ due t  a contribution by the random displ c ments for a finite number of sc ns ( SN ): 
)1/()( 222  Sni NSD   (see (145)). U ing σ, th s b as was c rrected for. Thu  btaine  maps of Σ and σ 
were used in figures 2-4.
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Construction of the population averaged CTV surface (popCTV)  
A specific patien  averag shape i  chosen ( aS ,1 ) and non-rigid transform tions { iF } from aS ,1  to aiS ,  are 
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The corresponding SDs of random displacements along the surfac  normals, )(kni , were calculated using,  
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Population systematic and rando  r i  i l  
The system tic and random residue i placements defin d in Eq. (6) resp. (7) are defined on the surfac  points 
of each patient specifi  v rage CTV urface iS , . W  c n map these point  onto popCTV sing the non-rigid 
transform tion of Eq. (4). Thus, we obtain PN values of ni  and ni at each point span ing popCTV. The 
population rand m displacement σ is calculated by taking the root me  square average of the PN  patient 
specific random errors n  at each point on the p pCTV surface.  
Although ni  is an unbiased esti ator of the systematic displa ement for patient i, its standard devi tion, SD( ni ) 
slightly overestimates Σ due to  contributi  by the rando  displacements for a finite umber of sc ns ( SN ): 
)1/()( 222  Sni NSD   (see (145)). Using σ, this bias was corrected for. Thus obtained m ps of Σ and σ 
were used in figures 2-4.
) lightly over stimates Σ due to a contribution by the random displ cements for  finite number 
of scans ( SN ): 
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Construction of the population averaged CTV surface (popCTV)  
A specific patient average shape is chosen ( aS ,1 ) and non-rigid transformations { iF } from aS ,1  to aiS ,  are 
obtained. Similar to Eq. (2), the vector fields iV that map the average surface of patient 1 onto that of p tient i 
)1( PNi   are   
 
 aaiii SSFV ,1, )(         (4) 
 
Again, 01 V  by definition. The popCTV surface is obtained as 
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where avgV  is the average over i of the fields }{ iV . 
 
Patient specific systematic and random residue displacements 
At ach point k )1( 1,iNk   spanning the average surface aiS , of patient i, the systematic displacement )(kni  
along the surface normal )(kni
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The correspond ng SDs of random displacements along the surface normals, )(kni , were calculated using,  
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Population systematic and random residue displacements 
The systematic and random residue displacements defined in Eq. (6) resp. (7) are defined on the surface points 
of ch pati nt specific v rage CTV surface aiS , . We can map these points onto popCTV using the non-rigid 
transformation of Eq. (4). Thus, we obtain PN values of ni  and ni at each point spa ning popCTV. The 
population r ndom displacement σ is c lculated by taking the root me n square average f the PN  patient 
specific random error  n  at ach point on the popCTV surfac .  
Although ni  is an unbiased estimator of the syste atic displaceme t for patient i, its standard deviation, SD( ni ) 
slightly overe timates Σ due to a contri ution by the ran om displacements for a finite number of sca s ( SN ): 
)1/()( 222  Sni NSD   (see (145)). Usi  σ, this bias was corrected for. Thus obtained m ps of Σ and σ 
were used in figures 2-4.
 (se  (145)). Using σ, this bias w  corrected for. Thus ob-
tained maps of Σ and σ were used in figures 2-4.
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radiotheraPy for Prostate cancer
Prostate cancer is the most common type of cancer, with the exception of skin cancers, for 
men in Western countries (82) and is treated with external beam radiotherapy in a large num-
ber of patients. This leads to grade 2 late gastrointestinal toxicity in 11%-33% of the patients, 
grade 2 late urinary toxicity in 10%-39% and erectile dysfunction in 36%-56% (5,81,146,147). 
This makes erectile dysfunction one of the most common sequelae of external beam radio-
therapy for prostate cancer. A decrease in sexual function is a common side effect in all forms 
of treatment for prostate cancer and is associated with impaired quality of life (37,38). A large 
number of patients would benefit from a technique that could reduce the risk of erectile dys-
function after external beam radiotherapy. Sparing a structure that is responsible for erectile 
dysfunction or reducing the treatment margin by using fiducial markers and on-line position-
ing corrections represent two possibilities to achieve this goal.
imPortance of sexual functioninG
Prostate cancer patients treated with external beam radiotherapy are approximately between 
50 and 80 years of age (81). There is a decline in several aspects of sexual function during 
aging and one might wonder whether this population still has desire for sex and adequate 
erections.
In the Dutch Krimpen study (148) 88% of the 1605 men between the age of 50 and 78 years 
were sexually active and the prevalence of significant erectile dysfunction was no more than 
26% in the highest age stratum of 70-78 years. Significant erectile dysfunction was defined 
as “severely reduced rigidity” or “no erections”. In a Swedish study from Helgason et al. (149) 
sexual function was studied in 319 men between 50 and 80 years of age. Of those men, 68% 
reported erectile stiffness “sufficient for intercourse most of the time” and 88% reported to 
have at least some sexual desire.
Incrocci et al. (45) studied 158 patients with localized prostate cancer. Of those patients, 
41% indicated to have (very) much sexual desire and sex was important to 78%. 
This is in agreement with the results reported in Chapter 2, in which 28% of the patients 
suffered from erectile dysfunction in the two weeks before radiotherapy, 40% found sex (very) 
important, 41% had considerable to very much desire and 51% was sexually active. Two years 
after radiotherapy, 36% of the patients had developed erectile dysfunction. Other prospective 
studies reported percentages from 7% to 59% (7-12). Helgason et al. (37) found that most 
men were distressed when external beam radiotherapy for prostate cancer led to a decrease 
in sexual function. 
In summary, most patients between 50 and 80 years of age are sexually active and have 
sexual desire. Unfortunately, radiotherapy for prostate cancer causes erectile dysfunction in 
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a considerable amount of patients. Therefore, a large group of patients would benefit from 
techniques that reduce the risk of erectile dysfunction after external beam radiotherapy.
sParinG structures resPonsible for erectile dysfunction
Erectile dysfunction after external beam radiotherapy for prostate cancer might be prevented 
by avoiding certain anatomical structures in the treatment plan. Then, a new question arises: 
what structure should be spared? Chapter 3 gives an overview of clinical studies that tried to 
find a correlation between erectile dysfunction and the radiation dose to the neurovascular 
bundles, the penile bulb and/or the corpora cavernosa (17-22,26-31,57,60,61,84). Most stud-
ies are hampered by a limited number of patients and have contradictory results. Therefore, 
there is no clear answer which structure is responsible for erectile dysfunction.
The majority of studies previously published did not take into account the use of hormonal 
therapy or potency aids and/or were retrospective in nature. Chapter 4 describes the largest 
study analyzing the correlation between the radiation dose to the corpora cavernosa and 
erectile dysfunction after external beam radiotherapy for prostate cancer. Even though this 
was a prospective study, taking into account hormonal therapy and the effects of potency 
aids, no significant correlation was found.
Erectile dysfunction after external beam radiotherapy for prostate cancer could be multi-
factorial instead of only based on the radiation damage to one single anatomical structure. 
If this is the case, it will be much harder to find a correlation between erectile dysfunction 
and the radiation dose to a specific structure. Furthermore, it is very well possible that the 
structure responsible for erectile dysfunction has not been investigated yet, like the internal 
pudendal arteries which supply the cavernosal arteries (75). Several studies have demon-
strated a reduced flow in the cavernosal arteries in patients suffering from erectile dysfunc-
tion after radiotherapy for prostate cancer (32-34). Moreover, the current dose calculations of 
these studies are based on one (planning) CT scan. However, there can be differences in the 
dose distribution calculated on the base of one CT scan and the actual dose distribution that 
is delivered to the patient (129,150,151). Fortunately, new techniques, like the use of fiducial 
markers, reduce setup errors (133) and therefore will make dose distribution analysis in the 
future more precise.
Furthermore, because of the close proximity of several anatomical structures possibly 
involved, the radiation dose to one structure is often correlated to the structure adjacent to 
it, like the penile bulb and the corpora cavernosa (18,20,63). Therefore the evidence which 
structure is responsible for erectile dysfunction can not be purely based on a dose correlation. 
Before such a conclusion can be drawn, a randomized controlled trial must be undertaken in 
which the responsible structure is spared in one arm.
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Another way to analyze this problem is by of animal experimental studies. Carrier et al. 
(74) conducted an experiment in which rats were treated at the prostatic area with one single 
fraction of 10 or 20 Gy and found a decrease in nitric oxide synthase-containing nerve fibres 
in the proximal shaft of the penis. Nitric oxide is believed to be the principal neurotransmitter 
mediating penile erection (152). Furthermore, the authors concluded that there were defects 
in the vascular supply of the erectile tissue and there was a decrease in cavernous smooth 
muscle. Merlin et al. (77) performed a similar experiment. The level of endothelin-1, a potential 
vasoconstrictor (78), was increased in rats treated with one single fraction of 20 Gy. Merlin 
et al. suggested that an increased endothelin-1 level could be involved in development of 
atherosclerotic lesions, because endothelin-1 acts as an autocrine growth factor for smooth 
muscle cells in the corpus cavernosum and pelvic vasculature (77).
However, in clinical practice not one single fraction, but multiple fractions are used to 
treat prostate cancer. Chapter 5 describes the changes in the penile arteries after fractionated 
irradiation of the prostatic area of the rat. Our pilot study shows that arterial changes, like 
thickening of the intima and occlusions, like suggested by Merlin et al. (77) and Carrier et al. 
(74) also develop after fractionated radiotherapy. However, future larger studies are needed to 
draw final conclusions and investigate the mechanism that caused these changes
marGin reduction
By reducing the CTV-PTV margin, all structures surrounding the prostate receive a lower radia-
tion dose, including the structures that are essential to a penile erection. The CTV-PTV margin 
accounts for uncertainties regarding movement, deformation and delineation. By reducing 
one or more of those uncertainties the treatment margin can be reduced without compromis-
ing target coverage.
The uncertainty regarding movement can be decreased by using stereographic targeting 
which is being described in Chapter 6. The prostate is implanted with 3 to 4 small golden 
cylinders, fiducial markers. These fiducial markers are identified in the planning CT scan, on 
which the prostate is delineated. Before each treatment fraction these fiducial markers are 
digitally imaged. The difference between the reference position and the current position of 
the fiducial markers is calculated and the treatment couch is shifted in order the correct the 
difference, within a threshold of 2 mm. Without marker-based correction protocols this differ-
ence could exceed 10 mm, while by using stereographic targeting this difference was reduced 
to <3 mm. Furthermore, the procedure is performed within 45 seconds per treatment fraction. 
A new development is the implantation of electromagnetic transponders that can be traced 
in real time without the use of X-ray beams (153). 
Another possibility is the use of cone beam CT scans, in which a scan is made on the actual 
treatment couch right before a treatment fraction (128). However, Moseley et al. reported that 
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the accuracy of prostate localization with cone beam CT scans is inferior to fiducial markers 
(154). Moreover, the acquisition of a cone beam CT scan plus the localization of the prostate 
in the cone beam CT scan takes several minutes. Cone beam CT scans are therefore not very 
attractive for online positioning corrections. Although several attempts have been made to 
use ultrasound for accurate prostate localization, the results have not been very promising 
(155,156).
A treatment margin is not only needed for movement of prostate but also for deformation 
of the prostate. To calculate the extent of margin reduction that can be gained by stereo-
graphic targeting, one must quantify the deformation of the prostate relative to the fiducial 
markers. Chapter 7 describes a repeat CT study in which this deformation is quantified and a 
new margin is suggested. This new margin, 5 mm for the prostate and 9 mm for the seminal 
vesicles, is a large improvement on the previously used 1 cm margin for the prostate and 
vesicles. This new margin has also been clinically implemented.
In future the use of magnetic resonance imaging (MRI) may possibly reduce the uncer-
tainty caused by delineation of the prostate. Because of better soft tissue visualization on 
MRI one might expect that delineation becomes more accurate, which can be analyzed with 
the inter- and intra-observer variation of the delineation. Rasch et al. found no significant 
differences in overall observer variation between axial CT and axial MRI scans (157). However, 
the observers outlined the CT scan while a hardcopy of the MRI scan was available to the 
observers at the same moment. Wachter et al. found no significant difference in interobserver 
variation in defining the apex in axial CT and axial MRI (158). They did find, not surprisingly, a 
significant difference between defining the apex in axial CT and sagittal MRI scans, in favour 
of the MRI. Unfortunately, no sagittal reconstructions of the CT scans were taken into the 
comparison. Villeirs et al. reported a significant decrease in interobserver variation, when the 
CT scan was recontoured with the addition of an axial, sagittal and coronal MRI scan and the 
help radiologist (159). Although, it is expected that better soft tissue visualization will lead to 
lower delineation variation, so far there is no good evidence to support this hypothesis.
Although there is no evidence that MRI will reduce the uncertainty of delineation, the vol-
ume of the prostate on MRI is a factor 1.1 to 1.4 smaller than on a CT scan (157-162). Several 
authors have suggested that on a CT scan the soft tissue structures surrounding the prostate 
might be included into the prostate volume (157,159-161). A MRI scan provides better soft 
tissue visualization making it easier to differentiate the prostate from the rectal wall, the 
neurovascular bundles, the venous plexus, the fibromuscular stroma, the levator ani muscles 
and the urogenital diaphragm. Furthermore, there is a good correlation between the volume 
of the prostate on MRI and radical prostatectomy specimens (163). Despite the controversy 
on the role of the penile bulb, one study already reported that prostate delineation on MRI 
reduces the dose to the penile bulb significantly (164).
Another way to reduce the irradiated volume and thereby healthy tissue surrounding the 
prostate, is not treating the entire seminal vesicles. If the risk of seminal vesicle invasion is low, 
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it is not necessary to include the seminal vesicles in the CTV. If there is a reasonable or high 
risk of seminal vesicle invasion, the whole vesicles will be irradiated. Some authors advise to 
include only a part of the seminal vesicles (143,165). This can reduce the radiation dose to 
the rectum, bladder and possible the neurovascular bundles as well. However, there are only 
a few studies on this subject, using pathological examination of prostatectomy specimens 
(143,166-169). The study populations consisted mainly of clinical T1 and T2 tumors. Seminal 
vesicle invasion was found in 9%-19% of the patients. If seminal vesicle invasion was found, 
the tips of the vesicles were involved in 0%-56%. Kestin et al. (143) advised to treat the seminal 
vesicles only in patients with higher risk (PSA ≥ 10 ng/ml, Gleason ≥ 7 or clinical stage ≥ T2b) 
and only to include the first 2.0 – 2.5 cm of the seminal vesicles in the CTV. They analyzed 
334 prostatectomy specimen of which 51 had seminal vesicles invasion. Only 10% of those 
51 patients with seminal vesicle invasion had tumor beyond the proximal 2.0 cm. However, it 
must be kept in mind that this study did not include any clinical T3 or T4 tumors.
The four other studies did not provide sufficient data on the depth of seminal vesicle inva-
sion (166-169). Therefore these studies can not be used to define which part of the seminal 
vesicles should be included in the CTV. So, the inclusion of only a part of the seminal vesicles 
in the CTV for T1 and T2 tumors with a reasonable risk of seminal vesicle invasion is supported 
by limited data. Furthermore, there is no evidence supporting the inclusion of only a part of 
the seminal vesicles in the CTV for T3 (or T4) tumors. 
marker imPlantation
There are two ways of implanting the fiducial markers into the prostate, either transperineal 
or transrectal. Since these two options lead to the same result, it seems logical to select the 
safest one. There are no studies comparing the risk of complications of these implantation 
methods, but there are a few studies, which compare transperineal and transrectal biopsies. 
Because a foreign body is implanted in the prostate, the risk for infection is important.
Thompson et al. performed an experiment with 45 patients divided into three equal 
groups (170). Fifteen patients were given a placebo antibiotic prophylaxis and underwent 
a transrectal biopsy. All of them had a positive blood culture from blood taken 5 minutes 
after the biopsy. Four of them were symptomatic with temperature above 37.6 °C or rigors. 
The same was done with 15 other patients, but they received 1g cefamandole instead of the 
placebo. Only 8 (53%) patients had a positive blood culture. One of them was symptomatic. 
The other 15 patients had a transperineal biopsy without antibiotics. Only 6 (40%) had a posi-
tive blood culture. None of them was symptomatic.
Vis et al. compared sextant transrectal versus sextant transperineal biopsies (171). A group 
of 1,687 men who had a transrectal biopsy at the ERSPC (European Randomized Study of 
Screening for Prostate Cancer), section Rotterdam, were compared with 431 men from their 
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ERSPC partner in Florence who had a transperineal biopsy. The patients with transrectal bi-
opsies were given antibiotic prophylaxis, while the patients with transperineal biopsies did 
not receive prophylaxis. The complication percentage for admittance to the hospital (0.4% 
versus 0.7%) and sepsis (0.18% versus 0.46%) were comparable, although more patients with 
transrectal biopsies needed antibiotic therapy, 3.1% versus 0.7%.
Langenhuijsen et al. were the only ones to describe the complications of transrectal marker 
implantation (172). They studied in a group of 209 patients. Fever was reported in 4% of these 
patients. However, this might be an underestimation, given the fact that 184 patients were 
analyzed retrospectively and received a questionnaire quite a long time, mean 90 weeks, after 
implantation.
There is only one small feasibility study on transperineal marker implantation by Henry et 
al. (173) with twelve patients. None of the patients reported any symptoms suggesting infec-
tion and the procedure was well tolerated by most patients.
Although there is no study comparing different ways of marker implantation the trans-
perineal approach, seems to be the safest option. Furthermore, we have not only chosen to 
implant the markers transperineally, but also to give antibiotic prophylaxis. 
Another issue that needs attention is swelling of the prostate because of edema by the 
implantation procedure. This is a well known problem in brachytherapy (101,104,174,175). 
The prostate volume can almost double because of this edema after brachytherapy (175). If 
this edema is not resolved before the planning CT is taken, the volume of the prostate will be 
too large in planning CT scan. If this is the case, the CTV will be too large and the gain of the 
fiducial markers might be lost. So far, there is no study analyzing this effect for fiducial marker 
implantation. In one brachytherapy study the half-life of this edema was 16 days after seed 
implantation with an average of 31 needles (174). Another brachytherapy study found a lower 
half life of 9 days after implantation with less needles, 18 needles on average (175). There is a 
significant correlation between the number of needles and the amount of swelling (174). In 
our institute only 2 needles are used to implant 3 to 4 fiducial markers and there is at least 
one week interval between the implantation and the planning CT scan. The fact that there 
are no big displacements of the markers after the planning CT scan as reported in Chapter 7, 
supports the idea that a week is sufficient time for most edema to resolve.
Gold is often used as it has a high specific gravity and it is commercially available. Other 
dense metals such as platinum, titanium and tungsten can also be used (176).
The markers have to be small to minimize morbidity and reduce the risk of marker overlap 
on the images. However, the markers must be large enough to be detected on MV images. 
Studies investigating marker size advise to use a marker size of 5.0 mm in length and 0.9 – 1.0 
mm in diameter (176,177).
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onGoinG studies
At the moment four studies are being conducted. One study is being undertaken to expand 
the current stereographic targeting protocol. The goal of this study is to perform stereograph-
ic targeting to correct for shifts of the prostate during a treatment fraction. This might allow a 
further reduction of the treatment margin.
The DOFAR study (DOse volume effects and Fibrosis After Radiotherapy for prostate cancer) 
will investigate the possible role of the internal pudendal arteries, by using repeat MRI scans. 
The internal pudendal arteries will be imaged before radiotherapy to calculate the radiation 
dose. The correlation between radiation dose to the internal pudendal arteries and erectile 
dysfunction will be analyzed. Furthermore, the internal pudendal arteries will also be imaged 
one and two years after radiotherapy to visualize possible fibrosis, or occlusion.
The pilot study, described in Chapter 5, demonstrated changes in the penile arteries of the 
rat after fractionated irradiation of the prostate. The results of this study enable the start of 
the second part of the study, in which the use of an endothelin A receptor antagonist will be 
evaluated. An endothelin A receptor antagonist has the potential to improve the flow in the 
penile arteries and might prevent radiation damage that leads to erectile dysfunction.
The HYPRO study, HYpofractionated irradiation for PROstate cancer, is a multicenter study 
aiming to include 800 patients. The goal is to demonstrate the superiority of the hypofraction-
ated schedule with respect to the relapse rate in combination with comparable toxicity. 
All patients are treated with reduced treatment margins, by using fiducial markers or cone 
beam CT scans. Both the EORTC-PR25 prostate module and the International Index of Erectile 
Function (IIEF) will be filled out by all patients (54). This study will give the answer whether or 
not a reduced treatment margin will lead to lower risk of erectile dysfunction.
conclusion 
Before investigating ways to prevent erectile dysfunction after external beam radiotherapy for 
prostate cancer, one question must be answered: to what extent does external beam radio-
therapy for prostate cancer cause erectile dysfunction? 
Most men are sexually active before external beam radiotherapy for prostate cancer. Two 
years after radiotherapy 36% of the pre-treatment potent patient suffer from erectile dysfunc-
tion (this thesis). So, preventing erectile dysfunction has the potential to improve to quality of 
life in a large number of patients.
The radiotherapy treatment plan can be adapted to spare specific anatomical structures 
that may cause radiation-induced toxicity. Several authors advised sparing of the penile bulb 
to preserve erectile function. However, this is not sufficiently supported by the current litera-
ture and the penile bulb plays little role in achieving or maintaining an erection (this thesis). 
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Other structures essential for an erection have mainly been analyzed in studies with a limited 
number of patients or have not been analyzed at all.
Previous studies reported a reduced flow in the cavernosal arteries in patients with erectile 
dysfunction.This could be caused by radiation damage to the internal pudendal arteries or 
the cavernosal arteries themselves. In the study with the largest number of patients so far, 
no correlation was found between the radiation dose to the corpora cavernosa and erectile 
dysfunction after external beam radiotherapy for prostate cancer (this thesis). Although, little 
is known about the statistical power to prove such a correlation. 
A pilot study shows that fractionated irradiation of the prostatic area of the rat leads to 
changes in the penile arteries, including thickening of the intima and occlusions (this thesis). 
This supports the hypothesis that arteries providing blood inflow in corpora cavernosa might 
be involved in erectile dysfunction after radiotherapy. The results of the clinical DOFAR study, 
investigating the internal pudendal arteries, hopes to shed some light on this topic.
Until it is clear which structure should be spared, the most feasible way to reduce erectile 
dysfunction is by minimizing the treatment margin and thereby lowering the radiation dose 
to all structures essential for a penile erection. A fast and accurate procedure to do daily on-
line repositioning of the prostate based on imaging of implanted markers was developed and 
implemented at our institute (this thesis).
Stereographic targeting allows a large improvement in positioning of the prostate before 
each treatment fraction. The deformation of the prostate relative to these implanted markers 
was quantified, enabling the calculating of a new treatment margin (this thesis). Stereographic 
targeting and the analysis of deformations of the prostate have led to a large reduction in the 
clinical treatment margins.
The decrease in the radiation dose of all structures essential for an erection is likely to 
improve erectile function after external beam radiotherapy for prostate cancer. 
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Summary
In this thesis the question is addressed whether there are possibilities to reduce or even pre-
vent the incidence of erectile dysfunction after external beam radiotherapy for prostate can-
cer. Chapter 1 is a general introduction into external beam radiotherapy for prostate cancer, 
the most common side-effect, erectile dysfunction, and possibly ways to reduce or prevent 
erectile dysfunction. In chapter 2 to chapter 7 six studies are described which answer different 
sub-questions. Chapter 8 answers the main question of this thesis whether erectile dysfunc-
tion after external beam radiotherapy for prostate can be prevented.
chaPter 1
Prostate cancer is the most common type of cancer in men in Western countries apart from 
basal and squamous cell skin cancers. A large part of the prostate cancer patients are treated 
with external beam radiotherapy. Unfortunately, this treatment leads to gastro-intestinal and 
genito-urinary toxicity and also to erectile dysfunction in a considerable amount of patients. 
This thesis will focus specifically on the erectile dysfunction. Finding new techniques to de-
crease the incidence of erectile dysfunction after external beam radiotherapy for prostate 
cancer, has a great potential to improve the quality of life after treatment in a vast number of 
prostate cancer patients.
chaPter 2
Since the introduction of three-dimensional conformal radiotherapy, there are only a few 
prospective studies available that provide a rate of erectile dysfunction. Furthermore, most 
of those studies have insufficient follow-up and/or do not take into account important con-
founding factors that influence sexual function. Chapter 2 is based on a Dutch multicenter 
Phase III dose escalation trial (trial code CKVO 96-10), in which patients with a localized adeno-
carcinoma of the prostate were randomized between prescribed dose levels of 68 Gy and 78 
Gy. Hormonal therapy, which has a large impact on sexual functioning, and potency aids were 
taken into account. There was no difference in erectile dysfunction between the different 
dose levels. However, there was a significant reduction in sexual activity in patients treated 
with adjuvant hormonal therapy. This supports the methodology to take hormonal therapy 
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into account, when assessing sexual function. One year after radiotherapy 27% of the pre-
treatment potent patients had developed erectile dysfunction. Two years after radiotherapy 
36% of 96 patients suffered from erectile dysfunction, after which the percentage stabilized.
chaPter 3
Finding an anatomic structure responsible for erectile dysfunction after radiotherapy will en-
able physicians to avoid a high radiation dose in this structure and has the potential to reduce 
erectile dysfunction after radiotherapy. In Chapter 3 we search for evidence in literature which 
anatomic structures should be spared. There are three major requirements for adequate 
penile erection: (i) functioning neurovascular bundels and cavernous nerves which supply 
the penis with nitric oxide, (ii) arterial inflow through the internal pudendal and cavernosal 
arteries and (iii) healthy erectile tissue in the corpora cavernosa which ensures adequate trap-
ping of blood in the penis to maintain erection (known as the veno-occlusive mechanism). 
Most studies have analyzed the correlation between the radiation dose to the penile bulb and 
erectile dysfunction. Several authors have already advised to spare the penile bulb. However, 
the penile bulb is not an essential structure to achieve or maintain an erection and the studies 
show contradicting results. The neurovascular bundles have been analyzed in studies with a 
small number of patients and no correlation between the dose in the neurovascular bundles 
and erectile dysfunction has been found. The corpora cavernosa have only been analyzed in 
four studies, showing different results. To our knowledge there is no study investigating the 
role of the internal pudendal arteries in erectile dysfunction after radiotherapy. 
chaPter 4
Chapter 3 shows that there is no clear evidence for sparing a certain anatomic structure to 
reduce the percentage of erectile dysfunction after radiotherapy for prostate cancer. Several 
studies have shown reduced flow in the cavernosal arteries and venous leakage of the corpora 
cavernosa after external beam radiotherapy. Unfortunately only one retrospective study, with 
only 28 patients, investigated the correlation between erectile dysfunction after external 
beam radiotherapy and the radiation dose to the corpora cavernosa. The study did not find 
any statistical correlation. Chapter 4 is also based on the CKVO 96-10 study. Ninety-six patients 
with 2 years of follow-up, who were not treated with hormonal therapy, were analyzed. No 
correlation was found between erectile dysfunction and the radiation dose to the corpora 
cavernosa or penile bulb.
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chaPter 5
Although several clinical studies investigated different anatomical structures, the cause of 
erectile dysfunction after radiotherapy is still largely unknown. There is some clinical evidence 
that damage to the arterial supply of the corpora cavernosa might be responsible. Chapter 
5 describes the first animal experimental study that analyzed the effect of fractionated ir-
radiation of the prostate on the penile arteries of the rat. The penis showed arteries which had 
developed loss of smooth muscle cells, thickening of the intima and occlusions. This prelimi-
nary data suggests that erectile dysfunction after radiotherapy might be caused by radiation 
damage to the arterial supply of the corpora cavernosa.
chaPter 6
There are two possible ways to reduce erectile dysfunction after radiotherapy. One is to 
find a specific anatomic structure that is responsible for erectile dysfunction and spare this 
structure during treatment. The other is an aspecific way, in which all structures surround-
ing the prostate receive less radiation dose. The clinical target volume (CTV) is an anatomical 
volume that contains demonstrated and suspected tumor considered to need treatment. In 
case of prostate cancer the CTV is the prostate, with or without seminal vesicles. To account 
for uncertainties regarding delineation, deformation and movement of the CTV a margin is 
added to the CTV. The planning target volume (PTV) is the CTV plus this margin. The CTV-PTV 
margin can be reduced below the commonly used 1 cm by using techniques that reduce the 
uncertainty regarding movement of the CTV. Chapter 6 describes such a technique, called 
stereographic targeting. Stereographic targeting was developed in our clinic to allow fast and 
fully automated accurate daily on-line positioning of the prostate by using implanted fiducial 
markers, orthogonal imaging and a remote controlled treatment couch. This new technique 
led to a reduction in standard deviations of the systematic (Σ) and random errors (σ) from 
4.0mm to <0.5mm and from 3.0mm to <0.8mm, respectively.
chaPter 7
Stereographic targeting allows a large improvement in positioning of the prostate. However, to 
safely reduce the CTV-PTV margin, information is required on the deformation of the prostate 
and seminal vesicles relative to the implanted fiducial markers. Twenty-one patients implanted 
with fiducial markers were analyzed by means of repeat CT scans. Intraobserver delineation er-
rors were up to 0.7 mm standard deviation. Deformation of the prostate was small with a stan-
dard deviation of about ≤ 1 mm. However, for the seminal vesicles deformation the standard 
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deviations went up to 3 mm. Chapter 6 provides data on the residu errors of stereographic 
targeting and previous studies have provided information on intrafraction motion. Since we 
now have information on delineation, deformation and movement of the prostate and seminal 
vesicles, a new CTV-PTV margin can be calculated. Chapter 7 indicates that a CTV-PTV margin 
of 5 mm for the prostate and 9 mm for the seminal vesicles could be used.
chaPter 8
Chapter 8 provides a general discussion and conclusion. At present there is no clear evidence 
that sparing a certain anatomic structure will lead to a reduction of erectile dysfunction after 
external beam radiotherapy for prostate cancer. However, the use of implanted fiducial mark-
ers and daily online setup corrections by using stereographic targeting does allow for a large 
reduction in the treatment margin. Consequently all structures surrounding the prostate, in-
cluding those essential for a penile erection, will receive less radiation. It is likely that this will 
also lead to a lower percentage of erectile dysfunction. The HYPRO study, which is now being 
conducted, will be able to confirm this hypothesis within a few years from now.
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Samenvatting
In dit proefschrift wordt de vraag beantwoord of er de mogelijkheden zijn om erectiele dis-
functie na uitwendige radiotherapie voor prostaatkanker te voorkomen. Hoofdstuk 1 geeft 
een algemene introductie over uitwendige radiotherapie voor prostaatkanker, de meest 
voorkomende bijwerking, namelijk erectiele disfunctie, en de mogelijkheden om erectiele 
disfunctie te verminderen dan wel te voorkomen. In hoofdstuk 2 tot en met hoofdstuk 7 
worden zes studies beschreven, waarin diverse subvragen worden beantwoord. Hoofdstuk 
8 beantwoordt de hoofdvraag van dit proefschrift: Is preventie van erectiele disfunctie na 
uitwendige radiotherapie voor prostaatkanker mogelijk?
hoofdstuk 1
Prostaatkanker is het meest voorkomende type kanker bij mannen in de westerse wereld 
met uitzondering van huidkanker. Een groot deel van de prostaatkanker patiënten wordt be-
handeld met uitwendige radiotherapie. Helaas geeft deze behandeling bijwerkingen in het 
maagdarmstelsel, de urinewegen en ook erectiele disfunctie bij een aanzienlijk deel van de 
patiënten. Dit proefschrift richt zich specifiek op erectiele disfunctie. Het vinden van technie-
ken om de kans op erectiele disfunctie te reduceren, heeft grote potentie om de kwaliteit van 
leven na behandeling te verbeteren voor een groot aantal prostaatkanker patiënten.
hoofdstuk 2
Sinds de introductie van drie-dimensionale conformele radiotherapie zijn er slechts enkele 
prospectieve studies die de kans op erectiele disfunctie beschrijven. Bovendien hebben de 
meeste van deze studies patiënten te kort gevolgd en/of houden zij geen rekening met 
andere factoren die seksueel functioneren beïnvloeden. Hoofdstuk 2 is gebaseerd op een 
Nederlandse multicentra fase 3 dosis escalatie studie (studie code CKVO 96-10), waarin pati-
enten met gelokaliseerd adenocarcinoom van de prostaat werden gerandomiseerd tussen de 
voorgeschreven dosisniveaus van 68 Gy en 78 Gy. Er werd rekening gehouden met hormonale 
therapie en middelen voor erectiestoornissen, aangezien deze een grote invloed hebben op 
het seksueel functioneren. Tussen beide dosisniveaus werd geen verschil in erectiele disfunc-
tie gevonden. Adjuvante hormonale therapie bleek echter wel tot een significante daling van 
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seksuele activiteit te leiden. Dit steunt de methodologie om rekening te houden met hormo-
nale therapie, indien seksueel functioneren geanalyseerd wordt. Eén jaar na radiotherapie 
had 27% van de patiënten die voor behandeling potent waren erectiele disfunctie ontwik-
keld. Dit percentage steeg tot 36% na twee jaar, waarna dit percentage stabiliseerde.
hoofdstuk 3
Het vinden van een anatomische structuur die verantwoordelijk is voor erectiele disfunctie na 
radiotherapie maakt het mogelijk deze structuur te sparen. Deze methode heeft een goede 
potentie om de kans op erectiele disfunctie na radiotherapie te verminderen. In hoofdstuk 3 
wordt gezocht naar bewijs in de literatuur welke structuur gespaard moet worden. Er zijn drie 
benodigdheden voor een adequate erectie: (i) functionerende neurovasculaire bundels en 
caverneuze zenuwen die stikstofmonoxide afgeven in de penis, (ii) arteriële instroom door de 
arteria pudenda interna en arteria cavernosa en (iii) gezond erectiel weefsel dat de veneuze 
uitstroom uit de corpora cavernosa voldoende belemmert om de erectie te behouden. De 
meeste studies hebben de correlatie tussen de bestralingsdosis in de peniele bulbus en erec-
tiele disfunctie geanalyseerd. Verscheidene auteurs hebben zelfs al geadviseerd de peniele 
bulbus te sparen. Echter, de peniele bulbus is geen essentiële structuur om een erectie te 
krijgen of te behouden en de studies laten tegenstrijdige resultaten zien. De neurovasculaire 
bundels zijn alleen geanalyseerd in studies met een klein aantal patiënten, waarbij in geen 
enkel geval een correlatie is gevonden tussen de dosis in de neurovasculaire bundels en 
erectiele disfunctie. De corpora cavernosa zijn slechts geanalyseerd in vier studies, welke ver-
schillende resultaten lieten zien. Er geen studie beschikbaar die de rol van de arteria pudenda 
interna bestudeert bij erectiele disfunctie na radiotherapie.
hoofdstuk 4
Hoofdstuk 3 laat zien dat er niet duidelijk bewezen is welke specifieke anatomische struc-
tuur gespaard moet worden om erectiele disfunctie na uitwendige radiotherapie voor pros-
taatkanker te verminderen. Verschillende studies hebben wel aangetoond dat de arteriële 
bloedstroom in de arteria cavernosa verlaagd is en dat er veneuze lekkage is bij de corpora 
cavernosa na uitwendige radiotherapie. Helaas is er maar één retrospectieve studie, met 
slechts 28 patiënten, die de correlatie heeft bestudeerd tussen erectiele disfunctie en de 
bestralingsdosis in de corpora cavernosa. Deze studie vond geen correlatie. Hoofdstuk 4 is 
ook gebaseerd op de CKVO 96-10 studie. Zesennegentig patiënten met een follow-up van 2 
jaar, die niet behandeld zijn met hormonale therapie, werden geanalyseerd. Er werd geen cor-
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relatie gevonden tussen erectiele disfunctie en de bestralingsdosis in de corpora cavernosa 
of de peniele bulbus.
hoofdstuk 5
Alhoewel meerdere klinische studies verschillende anatomische structuren hebben on-
derzocht, is de oorzaak van erectiele disfunctie na radiotherapie nog steeds grotendeels 
onbekend. Er is enig klinisch bewijs dat de schade aan de arteriële toevoer van de corpora 
cavernosa verantwoordelijk zou zijn. Hoofdstuk 5 beschrijft de eerste dierexperimentele stu-
die naar het effect van gefractioneerde bestraling van de prostaat op de vaten in de penis 
van de rat. De penis liet arteriën zien met verlies van gladde spiercellen, verdikking van de 
intima en occlusies. Deze voorlopige data suggereert dat erectiele disfunctie na radiotherapie 
voor prostaatkanker wellicht veroorzaakt wordt door schade aan de arteriële toevoer van de 
corpora cavernosa.
hoofdstuk 6
Er zijn twee mogelijkheden om de kans op erectiele disfunctie na radiotherapie te reduceren. 
De ene is het vinden van een specifieke anatomische structuur die verantwoordelijk is voor 
erectiele disfunctie en deze vervolgens te sparen tijdens de behandeling. De andere mogelijk-
heid is een aspecifieke manier, waarbij alle structuren rondom de prostaat een lagere bestra-
lingsdosis krijgen. Het klinisch doelvolume is een anatomisch volume dat de aangetoonde 
en verwachte tumor bevat die behandeld moet worden. In het geval van prostaatkanker 
is het klinisch doelvolume de prostaat, met of zonder zaadblazen. Om rekening te houden 
met de onzekerheden van intekening, deformatie en beweging van het klinisch doelvolume 
wordt er een marge toegevoegd aan het klinisch doelvolume. Het planning doelvolume is 
het klinisch doelvolume plus deze marge. Deze behandelingsmarge kan gereduceerd worden 
beneden de veelgebruikte 1 cm door gebruik te maken van technieken die de onzekerheid 
van beweging verminderen. Hoofdstuk 6 beschrijft een dergelijke techniek, genaamd stereo-
graphic targeting. Stereographic targeting werd ontwikkeld in ons ziekenhuis om een snelle 
en volautomatische accurate dagelijkse positionering van de prostaat mogelijk te maken. 
Dit wordt bereikt met behulp van in de prostaat geïmplanteerde goudmarkers, orthogonale 
afbeeldingen en een op afstand bestuurbare behandelingstafel. Deze nieuwe techniek heeft 
geleid tot een reductie in de standaard deviaties van de systematische en willekeurige fouten 
van respectievelijk 4.0 mm tot <0.5 mm en 3.0 mm tot <0.8 mm.
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hoofdstuk 7
Stereographic targeting maakt een grote verbetering van positionering van de prostaat mo-
gelijk. Om echter op veilige wijze de behandelingsmarge te reduceren is informatie nodig over 
deformatie van de prostaat en zaadblazen ten op zichte van de geïmplanteerde goudmarkers. 
Eénentwintig patiënten werden geïmplanteerd met 3 tot 4 goudmarkers en vervolgens wer-
den zij geanalyseerd met behulp van herhaalde CT scans. Intraobserver intekeningsfouten 
waren tot 0.7 mm standaard deviatie. Deformatie van de prostaat was klein met een standaard 
deviatie van ongeveer ≤ 1 mm. Echter, voor de zaadblazen ging de standaard deviatie van de 
deformatie tot 3 mm. Hoofdstuk 6 geeft data over de overblijvende afwijking na stereograp-
hic targeting en voorgaande studies hebben informatie gegeven over intrafractie beweging. 
Omdat we nu informatie hebben over intekening, deformatie en beweging van de prostaat 
en zaadblazen, kan een nieuwe behandelingsmarge berekend worden. Hoofdstuk 7 geeft aan 
dat een behandelingsmarge van 5 mm voor de prostaat en 9 mm voor de zaadblazen gebruikt 
kan worden.
hoofdstuk 8
Hoofdstuk 8 geeft een algemene discussie en conclusie. Op dit moment is er geen duidelijk 
bewijs dat het sparen van een bepaalde anatomische structuur zal leiden tot een reductie van 
erectiele disfunctie na uitwendige radiotherapie voor prostaatkanker. Echter, het gebruik van 
geïmplanteerde goudmarkers and dagelijkse positioneringscorrecties door middel van ste-
reographic targeting maakt het mogelijk de behandelingsmarge sterk te reduceren. Hierdoor 
krijgen alle structuren rondom de prostaat, inclusief diegene essentieel voor een erectie, een 
lagere bestralingsdosis. Het is waarschijnlijk dat dit ook zal leiden tot een lager percentage 
erectiele disfunctie. The HYPRO studie, die nu wordt uitgevoerd, zal deze hypothese binnen 
enkele jaren kunnen bevestigen.
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List of abbreviations
ASTRO american society for therapeutic radiology and oncology
aV xx absolute volume receiving xx gray
BT brachytherapy
CC corpora cavernosa
COM center of mass
Crura 1cm superiormost 1-cm segment of the crura
CS corpus spongiosum
CT scan computed tomography scan
CTV clinical target volume
DOFAR study dose volume effect and fibrosis after radiotherapy for prostate cancer study
DRR digitally reconstructed radiographs
DVH dose-volume histogram
D xx dose delivered to xx % of an anatomical structure
EBRT external beam radiotherapy
ED erectile dysfunction
EPID electronic portal imaging devices
ERSPC european randomized study of screening for prostate cancer
GJW Gerard Johan van der Wielen
Gy  gray
HE hematoxylin-eosin
HT hormonal therapy
HYPRO study hypofractionated irradiation for prostate cancer study
ICI intracavernosal injections
IGRT image guided radiotherapy
IIEF international index of erectile function
IMRT intensity modulated radiotherapy
IPA internal pudendal artery
kV(I) kilovoltage (image)
MEK marker extraction kernel
MR(I) magnetic resonance (imaging)
MU monitor units
MV(I) megavoltage (image)
n.a. not available
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NO nitric oxide
NVB neurovascular bundles
PB penile bulb
PDE5-inhibitors phosphodiesterase-5 inhibitors
popCTV population average CTV
PSA prostate specific antigen
PTV planning target volume
rV xx relative volume receiving xx gray 
SAc Dutch module on sexual activity
SD standard deviation
SF sexual function
SGT  stereographic targeting
SMA α-smooth muscle actin
TCSA theraview couch set-up assistent
TNT Theraview NT
Tonly translation only
T+R translation plus rotation
3D three-dimensional
3D-CRT three-dimensional conformal radiotherapy
Σ systematic error
σ random error
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Curriculum Vitae
Gerard van der Wielen werd op 5 januari 1979 geboren te Naarden. Het grootste deel van zijn 
jeugd groeide hij op in Leiden en behaalde zijn VWO diploma in 1997 aan het Stedelijk Gym-
nasium in Leiden. In datzelfde jaar begon hij aan zijn studie geneeskunde aan de Universiteit 
Leiden. In 2005 sloot hij zijn studie geneeskunde af met het keuze co-assistentschap urologie 
in het Leids Universitair Medisch Centrum. Dit werd gevolgd door zijn promotie onderzoek 
op de afdeling radiotherapie in samenwerking met de afdeling urologie in het Erasmus MC 
– Daniel den Hoed. In januari 2009 is hij begonnen aan de heelkundige vooropleiding in het 
ziekenhuis Bronovo (opleider dr. H.J. Smeets, chirurg) om deze in 2011 te vervolgen met zijn 
opleiding tot uroloog in het Hagaziekenhuis (opleider F.M.J.A. Froeling, uroloog) en het Leids 
Universitair Medisch Centrum (opleider prof.dr. R.C.M. Pelger, uroloog).
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Dankwoord
Het werk als full-time arts-onderzoeker is een aparte baan. Je begint aan een traject van 
enkele jaren, waarbij er aanvankelijk maar weinig zekerheden zijn. Welke artikelen ga je schrij-
ven? Gaat het überhaupt lukken om te promoveren? Zo ja, zal deze promotie dan bijdragen 
aan de zo gewilde opleidingsplek of had je toch beter in de kliniek kunnen blijven? Na de 
grote voldoening van de acceptatie van het eerste artikel begon langzamerhand het idee te 
groeien dat deze onzekerheden juist een grote vrijheid vormen. Als promovendus mocht ik 
mijn eigen tijd indelen, een grote stem hebben in de onderzoeksrichting en zelf een aantal 
artikelen schrijven.
Uiteraard is dit proefschrift niet het werk van mij alleen. In dit dankwoord wil ik iedereen 
bedanken zonder wie dit proefschrift niet mogelijk was geweest. 
Luca Incrocci, jij hebt mij als copromotor vrijheid gegeven en altijd vertrouwen in mij ge-
had. Ik kon altijd bij je binnenlopen om even kort te overleggen, wat dan vervolgens meestal 
uitliep tot minstens een uur. Jij was altijd bereikbaar en ieder manuscript of studieprotocol 
was binnen enkele dagen van suggesties, commentaar en correcties voorzien. Dit heeft zeker 
bijgedragen tot het op tijd afronden van het proefschrift.
Hans de Boer, pas op een laat moment werd jij officieel mijn copromotor, maar al lang voor 
die tijd heb jij mij begeleid alsof je mijn copromotor al was. Wij hebben samen met Theodore 
vele discussies gevoerd die met name fysisch van aard waren. Jij hebt de tijd genomen mij 
deze zaken uit leggen en ik heb het enorm gewaardeerd dat de toevoegingen aan de discus-
sies van een niet-fysicus serieus werden genomen.
Theodore Mutanga, nadat we éénmaal bij elkaar op de kamer zijn gekomen, hebben we 
een goede samenwerking opgebouwd. Zonder jouw inzet voor hoofdstuk 6 en 7 had ik niet 
kunnen promoveren. Succes met het afronden van jouw promotie!
Dokter Kirkels, u heeft mij begeleid bij de opstart van het implanteren van goudmarkers in 
de prostaat op de Daniel den Hoed. Daarnaast heeft u mij geleerd deze goudmarkerimplan-
taties zelfstandig uit te voeren. Het zelfstandig kunnen verrichten van een essentieel klinisch 
deel van mijn onderzoek, heeft mij grote voldoening gegeven. 
Shafak Aluwini, we zijn een mooi team geworden voor de markerimplantaties. Dankzij 
jouw inzet hoef ik mij geen zorgen te maken over de voortzetting van het onderzoek.
De dames van de functiekamer, Rolien Vonk, Daphne Arias, Marijke Bernhard en Nel de 
Jonge, zijn flexibel genoeg geweest om een nieuwe techniek, de goudmarkerimplantaties, 
een plaats te geven op de funktiekamer. 
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Mischa Hoogeman, jij hebt klaargestaan voor mijn ideeën en hebt gezorgd voor software 
waarmee ik een aantal ideeën heb kunnen uitwerken. Hoofdstuk 4 is tot stand gekomen dank-
zij jouw hulp.
Hoofdstuk 5 was er absoluut nooit geweest zonder de goede inzet en zeer noodzakelijke 
hulp in het basale onderzoek van Bas de Jong, Wytske van Weerden en Marcel Vermeij. Bas en 
Marcel hebben een essentiële rol gespeeld in het verzamelen van de data. Wytske heeft mij 
geleerd hoe je een basaal wetenschappelijk artikel schrijft. Ik wil jullie bedanken voor de inzet 
van het laatste artikel van mijn proefschrift.
Beste professor Levendag, ik heb uw vertrouwen in mij altijd zeer gewaardeerd. Hoewel 
ik geen radiotherapeut ga worden, heb ik zeer nuttige radiotherapeutische kennis mogen 
opdoen op uw afdeling. Deze kennis zal zeker van pas komen in de urologie.
Beste professor Bangma, dankzij u ben ik op dit promotietraject terecht gekomen en dank-
zij u is het afsluitende artikel ook gereedgekomen. Daarnaast heeft u mij de mogelijkheid 
gegeven om 2 maanden in uw kliniek te werken, om de urologische praktijk weer van dichtbij 
mee te maken.
De overige leden van de promotiecommissie, prof.dr. B.J.M. Heijmen, prof.dr.ir. J. Trapman 
en prof.dr. J.J. Battermann, dank ik voor hun interesse en beoordeling van het manuscript.
Verder ben ik veel dank verschuldigd aan een groot aantal andere personen: Wim van 
Putten, John Mulhall, Gert Dohle, Maarten Schuit, Hans Marijnissen, Dik Kok, Enno Collij, Erik 
Loeff, Ben Göbel, Davy Wentzler, Jaco Barnhoorn, Eliana Vasquez Osorio, Wilco Schillemans, 
Marjolein van Os, Hans Joosten, Ruud Kuipers, Jolanda van den Heuvel, Jacqueline van der 
Valk, Natasha de Haan, Steffanie Klosinski en nog vele anderen.
Uiteraard wil ook mijn ouders bedanken die mij altijd hebben ondersteund en gestimu-
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